hp09-2016sd: the supply and delivery of solid dosage … · [email protected] ranbaxy...

HP09-2016SD: THE SUPPLY AND DELIVERY OF SOLID DOSAGE FORMS TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 1 AUGUST 2016 TO 31 JULY 2018

2

1. IMPORTANT GENERAL INFORMATION:

1.1 Please note that the delivered price is for the unit of measure (UOM) offered. Unit of Measure, National Stock Numbers and prices should be carefully matched when placing or executing orders.

1.2 All prices are inclusive of 14 % VAT.

1.3 All prices are on a delivered basis. 1.4 Where 28-day packs are specified and 30-day packs awarded, this is not indicated

as a deviation from specification, but indicated in the unit column. This applies to the following pack sizes:

28 vs 30 56 vs 60

84 vs 90 100 vs 112

1.5 Where an item has been split between more than one supplier, a single NSN is

used, even if the awarded sizes differ as above.

1.6 Contact persons and e-mail addresses indicated hereunder are to be used for contract enquiries and not for orders.

2. NAMES AND ADDRESSES OF CONTRACTORS AND CONTACT DETAIL

Supplier Name Supplier

Code Postal Address Contact Detail:

Tel Number ---------------------Fax Number

Contact Person ---------------------- E-mail Address

Abbott Laboratories (Pty) Ltd

V2150 P O Box 7208 WELTEVREDEN PARK 1715

(011) 858-2250 (086) 231-2329

Neren Lorrick [email protected]

Accord Healthcare (Pty) Ltd

V2MB8 Postnet 182 Private Bag X51 RIVONIA 2128

(011) 234-5703 (011) 234-5700

Reshlan Nagoor [email protected]

Adcock Ingram Critical Care (Pty) Ltd

V4222 P O Box 6888 JOHANNESBURG 2000

(011) 494-8000 (086) 553-0460

Tahera Munshi [email protected]

Adcock Ingram Healthcare (Pty) Ltd

V2272 Private Bag X69 BRYANSTON 2021

(011) 635-0671 (086) 553-0671

Louis Fourie [email protected]

Akacia Healthcare (Pty) Ltd

V0DM6 P O Box 194 ISANDO 1600

(087) 357-6077 (086) 618-8442

Sue Venter [email protected]

AstraZeneca Pharmaceuticals (Pty) Ltd

V2180 Private Bag X23 BRYANSTON 2021

(011) 797-6166 (086) 676-5948

Singatwa Mnqandi [email protected]

Austell Laboratories (Pty) Ltd

V1A10 P O Box 1110 CROWN MINES 2025

(011) 611-1400 (011) 839-0401

Younus Karolia [email protected]

Bayer (Pty) Ltd V6390 P O Box 143 ISANDO1600

(011) 921-5279 (011) 921-5272

Magda Noack [email protected]


3

Supplier Name Supplier Code

Postal Address Contact Detail:



Biotech Laboratories (Pty) Ltd

VUV35 Suite 150 Private Bag X65 HALFWAY HOUSE 1685

(011) 848-3050 (011) 848-3065

Duduzile Mofolo [email protected]

Cipla Medpro South Africa (Pty) Ltd

VXZ32 P O Box 32003 MOBENI 4060

(011) 315-9150 (021) 914-0531

Willem Maritz [email protected]

Dezzo Trading 392 (Pty) Ltd

V05Y6 P O Box 725 LAWLEY 1824

(011) 857-2090 (086) 265-2233

Omar Matthews [email protected]

Dr Reddy's Laboratories (Pty) Ltd

V1A08 P O Box 784746 SANDTON 2146

(011) 324-2112 (011) 388-1262

Lorraine Keyser [email protected]

Equity Pharmaceuticals (Pty) Ltd

V1QZ3 P O Box 60964 PIERRE VAN RYNEVELD 0045

(012) 345-1747 (012) 345-1412

Benjamin Miny [email protected]

Ferring Pharmaceutical (Pty) Ltd

VXY92 P O Box 14358 CLUBVIEW 0014

(012) 345-6358 (012) 345-1156

Mercia van Zyl [email protected]

Gulf Drug Company (Pty) Ltd

VTS03 P O Box 1523 DURBAN 4000

(031) 538-8700 (031) 502-2379

Kevin Moonsamy [email protected]

Innovata Pharmaceuticals (Pty) Ltd

VBBL4 P O Box 777 KELVIN 2054

(086) 999-0912 (086) 585-5129

Imraan Suliman [email protected]

Litha Pharma (Pty) Ltd

VGS73 P O Box 83 MIDRAND 1685

(087) 742-1691 (087) 742-1666

Barry Budler [email protected]

Meda Pharma South Africa (Pty) Ltd

V2ZD6 Post Net Suite #166 Private Bag X9976 SANDTON 2196

(011) 302-1260 (011) 784-1428

Riaan Botes [email protected]

Medicine Developers International (Pty) Ltd

V3LJ8 P O Box 725 LAWLEY 1824

(011) 857-2090 (086) 265-2233

Omar Matthews [email protected]

Merck (Pty) Ltd V3018 P O Box 1998 HALFWAY HOUSE 1685

(011) 957-2989 (086) 652-8217

Bev Brits [email protected]

Mirren (Pty) Ltd V7149 P O Box 12348 BENORYN 1504

(011) 425-4026 (011) 425-0808

Maureen Kruger [email protected]

Mylan (Pty) Ltd V3PS6 Postnet Suite 23 Private Bag X10010 EDENVALE 1610

(011) 451-1300 (011) 451-1400

Nathi Mthethwa [email protected]

Novartis South Africa (Pty) Ltd

VBVW2 P O Box 12257 VORNA VALLEY 1686

(011) 347-6846 (011) 929-2479

Darisha Singh [email protected]


4

Supplier Name Supplier Code

Postal Address Contact Detail:



Pfizer Laboratories (Pty) Ltd

V2189 P O Box 783720 SANDTON 2146

(011) 320-6000 (011) 895-1491

Themba Mnguni [email protected]

Pharmacare Limited V2205 P O Box 1593 GALLO MANOR 2052

(011) 239-6243 (086) 574-3175

Jaco De Wet [email protected]

Pharmaceutical Contractors (Pty) Ltd

VCJF7 P O Box 427 ISANDO 1600

(011) 974-1631 (011) 974-7520

Claudio Manoel Martins [email protected]

Pharmachem Laboratories (Pty) Ltd

V3LA8 Private Bag X12 PRETORIA WEST 0117

(012) 749-4800 (086) 575-4622

Bilaal Jeewa [email protected]

Pharmaco Distribution (Pty) Ltd

VBVW1 P O Box 786522 SANDTON 2146

(011) 784-0077 (011) 784-6994

Jan van den Berg [email protected]

Portfolio Pharmaceuticals (Pty) Ltd

VWB81 P O Box 591292 KENGRAY 2100

(011) 334-5530 (011) 334-9521

Jenny Holland [email protected]

Ranbaxy Pharmaceuticals (Pty) Ltd

V4728 P O Box 43486 INDUSTRIA 2042

(012) 643-2000 (086) 662-7031

Deepak M Sewnarain [email protected]

Ranbaxy South Africa (Pty) Ltd

VVZ04 P O Box 10458 CENTURION 0046

(012) 643-2000 (086) 662 7031

Deepakh M Sewnarain [email protected]

Resmed Healthcare CC

VCEJ2 P O Box 65409 RESERVOIR HILLS 4090

(031) 577-7258 (031) 577-7182

Laljith Sunker Singh [email protected]

Roche Products (Pty) Ltd

V2177 P O Box 55922 NORTHLANDS 2196

(011) 502-5000 (011) 268-5738

Mongezi Sokanyile [email protected]

Sandoz SA (Pty) Ltd VVZ69 P O Box 154 ISANDO 1600

(011) 929-9002 (011) 394-5935

Renee Moodley [email protected]

Sanofi-Aventis South Africa (Pty) Ltd

V2160 Private Bag X207 MIDRAND 1683

(011) 256-3750 (086) 646 4833

Gavin Bauer [email protected]

Zentiva South Africa (Pty) Ltd

VBVW0 Private Bag X207 MIDRAND 1683

(011) 256-3750 (086) 646-4833

Gavin Bauer [email protected]

Zinplex Marketing CC

V22Z6 P O Box 678 GARSFONTEIN 0042

(086) 111-9462 (012) 803-9283

Hermanus J H Fourie [email protected]

HP09-2016SD: Solid Dosage Forms Contract Circular Period 1 August 2016 to 31 July 2018

Item No

Item Description Quantity Awarded

% Split Supplier Name Supplier Code

Brand Name Delivered Price

Unit Pack Lead time (Days)

MOQ Total Score

NSN UOM

1 Acetazolamide 250mg tablet, 28 tablets

124 783 Adcock Ingram Healthcare (Pty) Ltd

V2272 Azomid R 19.6247 30 tablets 14 1 shipper (72 packs)

95.00 189752737 CO

2 Acetazolamide 250mg tablet, 100 tablets


V2272 Azomid R 46.4195 100 tablets 14 1 shipper (50 packs)

95.00 189710142 CO

4 Acetylcysteine 200mg tablet, 25 tablets

8 620 Sandoz SA (Pty) Ltd VVZ69 ACC 200mg 25 EFF tabs

R 46.0300 25 tablets 14 100 94.00 181896924 EA

5 Acitretin 10mg capsule, 28 capsules

5 654 Akacia Healthcare (Pty) Ltd

V0DM6 Neotigason 10mg R 603.6900 30 capsules 14 1 90.00 180179717 CO

6 Acitretin 25mg capsule, 28 capsules


V0DM6 Neotigason 25mg R 1 275.3100 30 capsules 14 1 90.00 180179725 CO

7 Alendronic acid 10mg tablet,28 tablets

61 378 Accord Healthcare (Pty) Ltd

V2MB8 Ostena 10mg R 20.5200 28 tablets 14 20 94.00 181918030 CO

8 Alfacalcidol 0,25mcg capsule, 28 capsules

81 265 Adcock Ingram Critical Care (Pty) Ltd

V4222 One-Alpha Capsules 0.25ug

R 168.5718 30 capsules 14 1 box 95.00 189712166 CO

9 Alfacalcidol 1mcg capsule, 28 capsules

37 188 Adcock Ingram Critical Care (Pty) Ltd

V4222 One-Alpha Capsules 1ug

R 527.9340 30 capsules 14 1 box 95.00 189714139 CO

10 Allopurinol 100mg tablet, 28 tablets

282 985 Austell Laboratories (Pty) Ltd

V1A10 Austell Allopurinol 100

R 8.0290 28 tablets 14 600 99.00 181923347 CO




R 15.0200 56 tablets 14 300 99.00 181934797 CO




R 33.1850 100 tablets 14 160 99.00 180105006 CO

13 Allopurinol tablet 100mg, 500 tablets

9 712 Pharmacare Limited V2205 Puricos 100mg Tabs 500

R 262.4964 500 tablets 14 5 95.00 189710123 CO



V2272 Adco-Allopurinol 300mg

R 14.0585 30 tablets 14 1 shipper (72 Packs)

95.00 180339396 PG

15 Alprazolam 0,5mg tablet, 30 tablets

5 301 Cipla Medpro South Africa (Pty) Ltd

VXZ32 Zopax 0.5 R 9.5300 30 tablets 14 88 99.00 189714591 CO

16 Amantadine 100mg capsule, 20 capsules

26 446 Novartis South Africa (Pty) Ltd

VBVW2 Symmetrel 100mg capsules

R 105.5900 20 capsules 14 1 93.00 189710390 CO

17 Amiodarone 200mg tablet, 28 tablets

44 360 Biotech Laboratories (Pty) Ltd

VUV35 Bio-Amiodarone 200mg Tablets 30's

R 27.5000 30 tablets 14 20 98.00 189710641 CO

18 Amisulpride 50mg tablet, 28 tablets

44 217 Sanofi-Aventis South Africa (Pty) Ltd

V2160 Solian 50mg R 125.8200 30 tablets 14 10 94.00 181807811 CO

19 Amisulpride 200mg tablet, 28 tablets


V2160 Solian 200mg R 279.2000 30 tablets 14 10 94.00 181807812 CO

Page 1 of 28


Item No





MOQ Total Score

NSN UOM

20 Amitriptyline 10mg tablet, 28 tablets

1 284 697 Pharmacare Limited V2205 Trepiline 10mg Tabs 28

R 7.2390 28 tablets 14 140 95.00 180339402 PG


136 000 Pharmacare Limited V2205 Trepiline 10mg Tabs 100

R 25.5702 100 tablets 14 40 95.00 189710133 CO


4 032 855 Pharmacare Limited V2205 Trepiline 25mg Tabs 28

R 4.4000 28 tablets 14 100 95.00 189711829 CO



R 7.4000 56 tablets 14 100 95.00 189711830 CO



R 11.1600 84 tablets 14 60 95.00 189711831 CO


134 635 Gulf Drug Company (Pty) Ltd

VTS03 Gulf Amitriptyline 25

R 15.1100 100 tablets 14 240 98.00 189760812 BT




R 22.4000 168 tablets 14 120 98.00 181917346 CO




R 49.0200 500 tablets 14 50 98.00 189710122 CO

28 Amlodipine 5mg tablet, 28 tablets

11 747 484 37% Austell Laboratories (Pty) Ltd

V1A10 Austell Amlodipine 5mg

R 3.1920 28 tablets 14 600 95.73 181936075 CO


11 112 485 35% Dezzo Trading 392 (Pty) Ltd

V05Y6 Indo Amlodopine - 5

R 3.0800 30 tablets 14 500 95.00 181936075 CO


8 889 988 28% Cipla Medpro South Africa (Pty) Ltd

VXZ32 Ciplavasc 5 R 3.3300 28 tablets 14 660 91.69 181936075 CO


5 529 726 70% Accord Healthcare (Pty) Ltd

V2MB8 Amtas 10mg R 4.0500 30 tablets 14 240 94.00 181936074 CO



V1A10 Austell Amlodipine 10mg

R 4.6510 28 tablets 14 600 85.64 181936074 CO

34 Aspirin 100mg tablet, 28 tablets

900 000 Bayer (Pty) Ltd V6390 Bayer Aspirin Cardio 100

R 11.5700 30 tablets 14 1 x 30 91.00 181837065 CO

35 Aspirin 300mg soluble scored tablet, 14 tablets

31 550 631 Resmed Healthcare CC VCEJ2 Soluspirin 14's R 5.6886 14 tablets 14 500 x 14's 100.00 189753742 PG

36 Aspirin 300mg soluble scored tablet, 96 tablets

291 850 Resmed Healthcare CC VCEJ2 Soluspirin 96's R 38.7942 96 tablets 14 50 x 96's 100.00 189714405 CO

37 Atenolol 25mg tablet, 28 tablets

17 250 AstraZeneca Pharmaceuticals (Pty) Ltd

V2180 Tenormin 25 R 25.3900 30 tablets 10 10 95.00 180071921 CO

Page 2 of 28


Item No





MOQ Total Score

NSN UOM


7 604 848 70% Biotech Laboratories (Pty) Ltd

VUV35 Bio-Atenolol 50 Tablets 30's

R 2.7000 30 tablets 14 600 98.00 180339413 PG



1 496 000 Austell Laboratories (Pty) Ltd

V1A10 Tenopress 100mg Tablets

R 4.2980 28 tablets 14 480 99.00 180192290 PG

40 Atorvastatin 10mg tablet, 28 tablets

325 352 Mylan (Pty) Ltd V3PS6 Vastor 10mg R 11.1000 28 tablets 14 10 98.00 180142176 CO





43 Baclofen 10mg tablet, 30 tablets


VUV35 Bio-Baclofen 10 Tabs 30

R 17.0000 30 tablets 14 20 98.00 189710127 CO

44 Baclofen 25mg tablet, 30 tablets


VBVW2 Lioresal 25mg tablets

R 44.6300 30 tablets 14 1 93.00 189710126 CO

47 Bezafibrate 400mg tablet, 28 tablets

149 453 Sandoz SA (Pty) Ltd VVZ69 Bezafibrate 400mg 30 Tab

R 56.7600 30 tablets 14 50 94.00 180000649 CO

48 Biperiden 2mg tablet, 28 tablets

71 510 Pharmaco Ditribution (Pty) Ltd

VBVW1 Akineton R 23.2900 28 tablets 14 10 92.00 181934910 CO



VBVW1 Akineton R 46.4800 56 tablets 14 10 92.00 180339393 PG



VBVW1 Akineton R 69.7200 84 tablets 14 10 92.00 181934911 CO

54 Buspirone 10mg tablet, 56 tablets

2 652 Pharmacare Limited V2205 Pasrin-10 10mg Tabs 60

R 125.4000 60 tablets 14 10 95.00 189711839 CO

55 Cabergoline 0,5mg tablet, 4 tablets

15 967 Pfizer Laboratories (Pty) Ltd

V2189 Dostinex 0.5mg TAB, 4's

R 195.4400 4 tablets 14 1 93.00 180348494 CO

TO FOLLOW

Page 3 of 28


Item No





MOQ Total Score

NSN UOM

56 Calciferol 50 000 IU tablet, 100 tablets

23 193 Pharmacare Limited V2205 Lennon Calciferol 50 000 IU Tabs 100

R 198.4398 100 tablets 14 5 95.00 189759820 CO

57 Calcitriol 0,25mcg capsule, 30 capsules

10 756 Roche Products (Pty) Ltd

V2177 Rocaltrol 0,25mcg R 131.7200 30 capsules 14 1 pack 93.00 189710186 CO

58 Calcium carbonate 420mg equivalent to elemental calcium 168mg. Glycine 180mg chewable tablet, 168 tablets

1 501 328 Pharmaceutical Contractors (Pty) Ltd

VCJF7 PC Glycal Chewable 168's

R 7.8000 168 tablets 28 300 91.00 181860981 PG

59 Calcium, soluble tablet equivalent to elemental calcium 500mg,10 tabletsMCC registered required

7 186 812 70% Pharmaceutical Contractors (Pty) Ltd

VCJF7 PC Calcium 500 10's

R 5.8000 10 tablets 28 600 91.00 180964704 CO

59 Calcium, soluble tablet equivalent to elemental calcium 500mg,10 tabletsMCC registered required

3 080 062 30% Accord Healthcare (Pty) Ltd

V2MB8 Calcium Fizzy R 6.4400 10 tablets 14 50 units 84.07 180964704 CO

60 Calcium, soluble tablet carbonate equivalent to elemental calcium 500mg tablet, 30 tabletsMCC registered required

3 500 000 Zinplex Marketing CC V22Z6 Zinplex Calcium 500mg Dispersible Tablets

R 10.4400 30 tablets 14 100 units 90.00 181917243 CO

62 Captopril 25mg tablet, 60 tablets


VUV35 Bio-Captopril 25 Tablets 60's

R 10.0000 60 tablets 14 20 98.00 189710010 CO

63 Carbamazepine 200mg tablet, 28 tablets

1 489 530 Pharmacare Limited V2205 Degranol 200mg Tabs 28 B/B

R 12.9732 28 tablets 14 80 95.00 181892375 PG


3 530 532 Pharmacare Limited V2205 Degranol 200mg Tabs 56 B/B

R 18.8500 56 tablets 14 40 95.00 180339414 PG


278 761 Pharmacare Limited V2205 Degranol 200mg Tabs 84 B/B

R 27.0700 84 tablets 14 40 95.00 180339437 PG


397 861 Pharmacare Limited V2205 Degranol 200mg Tabs 100

R 36.2500 100 tablets 14 20 95.00 189710219 CO

68 Carbidopa 25mg and levodopa 100mg tablet, 100 tablets

157 979 Pharmacare Limited V2205 Carbilev 25/100mg Tabs 100

R 80.3700 100 tablets 14 10 95.00 189710283 CO

Page 4 of 28


Item No





MOQ Total Score

NSN UOM

69 Carbidopa 25mg and levodopa 250mg tablet, 100 tablets

31 862 Pharmacare Limited V2205 Carbilev 25/250mg Tabs 100

R 139.0800 100 tablets 14 10 95.00 189710383 CO

71 Carvedilol 6,25mg scored tablet, 28 tablets


VXZ32 Carloc 6.25 R 9.7300 30 tablets 14 120 units 99.00 180254416 CO

72 Carvedilol 12,5mg scored tablet, 28 tablets


VXZ32 Carloc 12.5 R 12.8400 30 tablets 14 100 units 99.00 180256023 CO

73 Carvedilol 25mg scored tablet, 28 tablets

1 958 558 Cipla Medpro South Africa (Pty) Ltd

VXZ32 Carloc 25 R 17.7600 30 tablets 14 100 units 99.00 180155487 CO

74 Cetirizine 10mg tablet, 28 tablets


V1A10 Austell Cetirizine 10mg

R 2.9840 28 tablets 14 100 99.00 189763014 CO

76 Chloroquine equivalent to Chloroquine base 150mg tablet, 100 tablets

175 812 Zentiva South Africa (Pty) Ltd

VBVW0 Nivaquine Tablets R 68.2500 100 tablets 14 10 94.00 189712624 CO

77 Chlorphenamine 4mg tablet, 10 tablets

7 995 265 Adcock Ingram Healthcare (Pty) Ltd

V2272 Allergex 10 R 1.2300 10 tablets 14 1 shipper (450 packs)

95.00 181821882 PG

78 Chlorphenamine 4mg tablet, 30 tablets


V2272 Allergex 30 R 1.9800 30 tablets 14 1 shipper (390 packs)

95.00 181917348 CO

79 Chlorpromazine 25mg tablet, 28 tablets


V2160 Largactil 25 R 11.0400 28 tablets 14 10 94.00 181868871 CO
















Page 5 of 28


Item No





MOQ Total Score

NSN UOM

86 Chlorpheniramine maleate 4mg tablet, 1000 tablets

12 890 Ranbaxy Pharmaceuticals (Pty) Ltd

V4728 Rhineton 4mg R 150.4800 1000 tablets 14 4 94.00 189751769 CO

89 Citalopram 20mg tablet, 28 tablets

2 289 901 Biotech Laboratories (Pty) Ltd

VUV35 Bio Citalopram 20 Tablets 30's

R 8.0000 30 tablets 14 20 98.00 181798136 CO

90 Clomipramine 25mg tablets, 50 tablets


VBVW2 Anafranil 25mg tablets

R 100.0000 50 tablets 14 1 93.00 181797926 CO

91 Clonazepam 0,5mg tablet, 84 tablets


V2177 Rivotril 0.5mg Tablets

R 34.5300 90 tablets 14 1 pack of 90 tablets

93.00 180000664 CO

92 Clonazepam 2mg tablet, 84 tablets

Product AwardedClonazepam 2mg tablet, Deviation: Pack Size: 100 tablets


V2177 Rivotril 2mg Tablets

R 79.3000 100 tablets 14 1 pack of 100 tablets

93.00 189752192 CO

97 Clozapine 25mg tablet, 84 tablets

Product AwardedClozapine 25mg tablet, Deviation: Pack Size: 100 tablets

87 306 Pharmacare Limited V2205 Aspen Clozapine 25mg Tabs 100

R 36.1038 100 tablets 14 20 95.00 189710069 CO

98 Clozapine 100mg tablet, 84 tablets

Product AwardedClozapine 100mg tablet, Deviation: Pack Size : 100 tablets

184 001 Pharmacare Limited V2205 Aspen Clozapine 100mg Tabs 100

R 115.5960 100 tablets 14 20 95.00 189710025 CO

99 Codeine phosphate 30mg tablet, 100 tablets

14 841 Pharmacare Limited V2205 A-Lennon Codeine Phosphate 30mg Tabs 100

R 414.6000 100 tablets 14 2 95.00 189759809 CO

101 Cyclizine 50mg tablet, 10 tablets


V2272 Adco-Cyclizine 50mg

R 5.6600 10 tablets 14 1 shipper (450 Packs)

95.00 189711824 CO

102 Danazol 100mg capsule, 60 capsules


VXZ32 Danogen-100 R 176.0000 60 capsules 14 5 99.00 180280770 CO

Page 6 of 28


Item No





MOQ Total Score

NSN UOM

103 Deferasirox 250mg dispersible tablet, 28 tablets

830 Novartis South Africa (Pty) Ltd

VBVW2 Exjade 250mg tablets

R 2 008.7800 28 tablets 14 1 93.00 181810861 CO

104 Deferasirox 500mg dispersible tablet, 28 tablets


VBVW2 Exjade 500mg tablets

R 4 017.5500 28 tablets 14 1 93.00 181810862 CO

106 Desmopressin 0,1mg tablet, 30 tablets

12 885 Ferring Pharmaceutical (Pty) Ltd

VXY92 DDAVP 0.1mg tablets

R 249.3600 30 tablets 14 5 90.00 180772047 CO

107 Desmopressin 0,2mg tablet, 30 tablets

3 846 Ferring Pharmaceutical (Pty) Ltd

VXY92 DDAVP 0.2mg tablets

R 409.2300 30 tablets 14 5 90.00 181795796 CO

111 Diazepam 5mg scored tablet, 100 tablets


V2177 Valium 5mg R 57.0000 100 tablets 14 1 pack of 100 tablets

93.00 180280749 CO

114 Diclofenac sodium 25mg enteric coated tablet, 500 tablets

40 430 Mylan (Pty) Ltd V3PS6 Mylan Diclofenac 25mg

R 42.1100 500 tablets 14 1 98.00 189710665 CO

116 Digoxin 0,25mg tablet, 14 tablets

534 014 Pharmacare Limited V2205 Purgoxin 0.25mg Tabs 14 B/B

R 10.5222 14 tablets 14 100 95.00 180323803 PG

117 Digoxin 0,25mg tablet, 28 tablets

899 761 Pharmacare Limited V2205 Purgoxin 0.25mg Tabs 28 B/B

R 14.3754 28 tablets 14 80 95.00 180323807 PG

119 Dinoprostone 0,5mg scored tablet, 10 tablets


V2189 Prostin E2 0.5mg Tab 10's

R 244.4000 10 tablets 14 1 93.00 189710531 CO

120 Domperidone 10mg film coated tablet, 100 tablets


VUV35 Bio-Domperidone 10 Tablets 100's

R 30.0000 100 tablets 14 120 x 100's 98.00 189710374 CO

121 Doxazosin 1mg tablet, 30 tablets

16 120 Mylan (Pty) Ltd V3PS6 Cardugen 1mg R 15.0400 30 tablets 14 10 98.00 189763011 CO

123 Doxazosin 4mg tablet, 30 tablets

207 368 Mylan (Pty) Ltd V3PS6 Cardugen 4mg R 28.5000 30 tablets 14 10 98.00 189763013 CO

125 Enalapril 5mg tablet,28 tablets

3 545 317 75% Pharmaceutical Contractors (Pty) Ltd

VCJF7 Hypace 5mg 28's R 3.0300 28 tablets 28 650 91.00 189710188 CO

125 Enalapril 5mg tablet, 28 tablets


V1A10 Austell Enalapril 5mg

R 3.4200 28 tablets 14 480 87.42 189710188 CO

Page 7 of 28


Item No





MOQ Total Score

NSN UOM


15 228 702 27% Pharmacare Limited V2205 Pharmapress 10mg Tabs 28

R 4.5500 28 tablets 14 260 87.59 189708531 CO



V05Y6 Enalapril Maleate 10mg - hexal

R 4.5500 28 tablets 14 200 87.59 189708531 CO




R 4.2040 28 tablets 14 480 99.00 189708531 CO


12 408 572 22% Akacia Healthcare (Pty) Ltd

V0DM6 Envas 10 R 5.0500 30 tablets 14 1 71.89 189708531 CO


7 038 095 75% Pharmacare Limited V2205 Pharmapress 20mg Tabs 28

R 7.4500 28 tablets 14 260 72.44 189710187 CO




R 5.9570 28 tablets 14 480 99.00 189710187 CO

129 Ferrous salt, providing 65 mg elemental iron, alone or in combination with other elements/vitamins tablet/capsule, 28 tablets/capsules Must be registered with the MCC

Product awardedFerrous Sulfate Co tablet, 28 tabletsDeviation: Contains 55mg elemental iron

8 228 571 Gulf Drug Company (Pty) Ltd

VTS03 Gulf Ferrous Sulphate Compound Tablets

R 3.4800 28 tablets 14 900 98.00 181923348 CO

Page 8 of 28


Item No





MOQ Total Score

NSN UOM





R 6.2900 56 tablets 14 900 98.00 181923349 CO



2 400 000 Gulf Drug Company (Pty) Ltd


R 8.7600 84 tablets 14 750 98.00 181923350 CO





R 11.4600 100 tablets 14 100 98.00 181892378 CO

Page 9 of 28


Item No





MOQ Total Score

NSN UOM

136 Fluoxetine 20mg tablet/capsule, 28 tablets/capsules

Product awardedFluoxetine 20 mg capsule, 28 capsules

1 294 131 Dezzo Trading 392 (Pty) Ltd

V05Y6 Prolax Capsules R 6.0000 28 capsules 14 150 95.00 189712353 CO

137 Fluoxetine 20mg tablets/capsules, 100 tablets/capsules

Product awardedFluoxetine 20 mg capsule, 100 capsules

281 447 Dezzo Trading 392 (Pty) Ltd

V05Y6 Prolax Capsules R 21.6300 100 capsules 14 100 95.00 180106075 CO

138 Folic acid 5mg tablet, 28 tablets MCC registration

8 639 742 33% Gulf Drug Company (Pty) Ltd

VTS03 Gulf Folic Acid 5 R 3.7100 28 tablets 14 900 98.00 189713751 CO

138 Folic acid 5mg tablet,28 tabletsMCC registration

7 464 000 29% Ranbaxy Pharmaceuticals (Pty) Ltd

V4728 Be-Tabs Folic Acid 5mg

R 8.2000 28 tablets 14 250 -14.92 189713751 CO

139 Folic acid 5mg tablet, 100 tablets MCC registration



140 Folic acid 5mg tablet, 1000 tabletsMCC registration



141 Furosemide 40mg tablet, 28 tablets


V1A10 Austell Furosemide 40mg

R 2.7890 28 tablets 14 100 99.00 180339712 PG




R 5.5300 56 tablets 14 100 99.00 181798154 PG




R 7.4100 84 tablets 14 80 99.00 181798156 PG




R 11.5140 112 tablets 14 100 99.00 181859966 PG


62 886 Mylan (Pty) Ltd V3PS6 Mylan Furosemide 40mg

R 28.5000 250 tablets 14 10 98.00 189711054 CO



R 114.0800 1000 tablets 14 1 98.00 189714165 CO

Page 10 of 28


Item No





MOQ Total Score

NSN UOM



R 540.8600 5000 tablets 14 1 98.00 189715350 CO



V2160 Lasix 500mg R 833.3200 100 tablets 14 10 94.00 189710019 CO

149 Gabapentin 100mg capsule, 100 capsules


VUV35 Biotech Gabapentin 100mg 100's

R 47.5000 100 capsules 14 100 x 100's 98.00 180103509 CO

150 Glibenclamide 5mg tablet, 28 tablets

1 269 072 60% Pharmacare Limited V2205 Glycomin 5mg Tabs 28 B/B

R 3.8000 28 tablets 14 240 95.00 180189209 PG

150 Glibenclamide 5mg tablet,28 tablets

846 048 40% Biotech Laboratories (Pty) Ltd

VUV35 Bio-Glibenclamide 5 Tablets 28's PRP

R 4.0500 28 tablets 14 400 x 28's 92.08 180189209 PG


1 231 189 60% Pharmacare Limited V2205 Glycomin 5mg Tabs 56 B/B

R 5.8000 56 tablets 14 140 95.00 180340162 PG


820 793 40% Biotech Laboratories (Pty) Ltd


R 6.0500 56 tablets 14 400 x 56's 94.12 180340162 PG




R 7.8000 84 tablets 14 400 x 84's 98.00 180340166 PG



VUV35 Bio-Glibenclamide 5 Tablets 100's

R 10.7000 100 tablets 14 360 x 100's 98.00 189710395 CO

154 Gliclazide 80mg tablet, 28 tablets


V1A10 Austell Gliclazide 80mg Tablets

R 10.1200 28 tablets 14 720 99.00 180106076 CO



V1A10 Austell Gliclazide 80mg Tablets

R 18.2750 56 tablets 14 300 99.00 180670486 CO



158 Glimepiride 1mg tablet, 28 tablets


V1A10 Austell Glimepiride 1mg

R 2.6930 30 tablets 14 100 99.00 181892379 CO

TO FOLLOW

TO FOLLOW

Page 11 of 28


Item No





MOQ Total Score

NSN UOM

159 Glimepiride 2mg tablet,28 tablets



R 3.8180 30 tablets 14 100 99.00 181892380 CO

160 Glimepiride 4mg tablet, 28 tablets



R 4.6000 30 tablets 14 100 99.00 181892381 CO

162 Haloperidol 0,5mg capsule, 56 capsules


V2189 Serenace 0.5mg Cap 60s

R 82.1300 60 capsules 14 1 93.00 189710286 CO

163 Haloperidol 1,5mg tablet, 100 tablets

227 334 Pharmacare Limited V2205 Tamide 1.5mg Tabs 100

R 17.6700 100 tablets 14 60 95.00 189710367 CO

167 Haloperidol 5mg tablet, 100 tablets

390 067 Pharmacare Limited V2205 Tamide 5mg Tabs 100

R 28.5000 100 tablets 14 40 95.00 189710327 CO

169 Hydralazine 25mg tablet,56 tablets

876 078 Sandoz SA (Pty) Ltd VVZ69 Hydralazine HCl 25mg 56

R 24.8200 56 tablets 14 100 94.00 181798157 PG

170 Hydralazine 25mg tablet, 84 tablets

79 980 Sandoz SA (Pty) Ltd VVZ69 Hydralazine HCl 25mg 84

R 34.9400 84 tablets 14 100 94.00 180091224 CO

174 Hydrochlorothiazide 12,5mg tablet, 28 tablets

47 628 025 Pharmacare Limited V2205 Ridaq 12.5mg Tabs 28

R 3.5226 28 tablets 14 240 95.00 181821883 PG

175 Hydrochlorothiazide 25mg tablet, 28 tablets

25 612 382 Pharmacare Limited V2205 Ridaq 25mg Tabs 28

R 3.8874 28 tablets 14 240 95.00 180190405 PG

177 Hydrochlorothiazide 25mg tablet, 500 tablets

4 300 Pharmacare Limited V2205 Ridaq 25mg Tabs 500

R 66.1086 500 tablets 14 15 95.00 189710322 CO

178 Hydrocortisone 10mg scored tablet, 100 tablets


V2272 Covocort tablets R 117.0908 100 tablets 14 1 shipper (50 packs)

95.00 189710516 CO

179 Hyoscine butylbromide 10mg tablet, 10 tablets

5 975 242 Pharmacare Limited V2205 Hyospasmol 10mg Tabs 10 B/B

R 33.2196 10 tablets 14 40 95.00 189711820 CO

Page 12 of 28


Item No





MOQ Total Score

NSN UOM

180 Hyoscine butylbromide 10mg tablet, 100 tablets

43 496 Pharmacare Limited V2205 Hyospasmol 10mg Tabs 100

R 238.2030 100 tablets 14 5 95.00 189712129 CO

182 Ibuprofen 200mg tablet, 15 tablets

11 622 687 50% Adcock Ingram Healthcare (Pty) Ltd

V2272 Betagesic 15's R 2.0900 15 tablets 14 1 shipper (240 packs)

95.00 180339460 PG



VTS03 Ibunate R 2.2800 15 tablets 14 900 89.82 180339460 PG



V05Y6 Ibusor 200 R 2.4600 15 tablets 14 1080 79.07 180339460 PG















1 657 977 Medicine Developers International (Pty) Ltd

V3LJ8 Bren-400 R 4.0600 15 tablets 14 720 95.00 181923355 CO



V1A10 Austifen 400 R 7.4100 30 tablets 14 300 99.00 181923356 CO


387 629 Medicine Developers International (Pty) Ltd





190 Indomethacin 25mg capsule, 100 capsules


VTS03 Gulf Indomethacin 25

R 13.1100 100 capsules 14 500 98.00 189714494 CO

TO FOLLOW

Page 13 of 28


Item No





MOQ Total Score

NSN UOM

191 Isosorbide dinitrate 5mg sublingual tablet, 50 tablets

766 067 Sandoz SA (Pty) Ltd VVZ69 Isosorbide Dinitrate 5mg 50

R 8.9300 50 tablets 14 100 94.00 189710453 CO

192 Isosorbide dinitrate 10mg tablet, 50 tablets


R 19.0500 50 tablets 14 100 94.00 189710403 CO

193 Isosorbide dinitrate 10mg tablet, 84 tablets


R 14.6600 84 tablets 14 100 94.00 180146434 CO

198 Isotretinoin 10mg capsule, 60 capsules

2 250 Litha Pharma (Pty) Ltd VGS73 Orantane 10mg R 142.5000 60 capsules 14 8 94.00 189712676 CO

199 Isotretinoin 20mg capsule, 60 capsules

5 490 Litha Pharma (Pty) Ltd VGS73 Oratane 20mg R 218.0000 60 capsules 14 6 94.00 189712688 CO

203 Lamotrigine 25mg tablet, 56 tablets


VXZ32 Epitec 25 R 25.5000 60 tablets 14 180 units 99.00 180108134 CO










208 Lansoprazole 30mg capsule, 14 capsules


VXZ32 Lansoloc 30 (14's)

R 6.9500 14 capsules 14 240 units 99.00 180053598 CO

209 Lansoprazole 30mg capsule, 28 capsules


VXZ32 Lansoloc 30 (30's)

R 12.1800 30 capsules 14 180 units 99.00 181814080 CO

210 Leflunomide 10mg tablet, 30 tablets

740 Adcock Ingram Healthcare (Pty) Ltd

V2272 Rheumalef 10mg R 352.8329 30 tablets 14 1 shipper (150 packs)

95.00 181753191 CO

211 Leflunomide 20mg tablet, 30 tablets


V2272 Rheumalef 20mg R 352.8329 30 tablets 14 1 shipper (150 packs)

95.00 181781164 CO

212 Levetiracetam 250mg tablet, 30 tablets

14 180 Dr Reddy's Laboratories (Pty) Ltd

V1A08 Redilev 250 R 37.6200 30 tablets 14 5 90.00 181934912 CO

Page 14 of 28


Item No





MOQ Total Score

NSN UOM

215 Levetiracetam 750mg tablet, 30 tablets


V1A08 Redilev 750 R 91.2000 30 tablets 14 5 90.00 181934915 CO

216 Levothyroxine sodium 0,05mg tablet, 28 tablets

755 831 Merck (Pty) Ltd V3018 Euthyrox 50ug 28's

R 5.0400 28 tablets 14 180 95.00 181860085 CO



R 15.7500 100 tablets 14 180 95.00 189710425 CO



R 6.9600 28 tablets 14 180 95.00 181860086 CO



R 22.1000 100 tablets 14 180 95.00 189710280 CO

221 Lithium carbonate 250mg tablet, 100 tablets

82 191 Pharmacare Limited V2205 Camcolit 250mg Tabs 100

R 160.7628 100 tablets 14 5 95.00 189710365 CO

222 Lithium carbonate 400mg tablet, 100 tablets

34 037 Pharmacare Limited V2205 Camcolit 400mg Tabs 100

R 223.2576 100 tablets 14 5 95.00 189710053 CO

223 Loperamide 2mg tablet, 6 tablets


V2272 Adco-Loperamide 2mg 6's

R 1.2700 6 tablets 14 1 shipper (176 packs)

95.00 189710479 CO

224 Loperamide 2mg tablet, 300 tablets


V2272 Adco-Loperamide 2mg 300's

R 22.4600 300 tablets 14 1 shipper (105 packs0

95.00 189710482 CO

225 Lorazepam 1mg tablet, 100 tablets

85 515 Pharmacare Limited V2205 Tranqipam 1mg Tabs 100

R 94.5858 100 tablets 14 10 95.00 189710157 CO

226 Lorazepam 2,5mg tablet, 100 tablets

26 364 Pharmacare Limited V2205 Tranqipam 2.5mg Tabs 100

R 148.1088 100 tablets 14 10 95.00 189714603 CO

227 Losartan 50mg tablet, 28 tablets


V1A10 Austell Losartan 50

R 7.6930 28 tablets 14 100 99.00 181936086 CO

228 Losartan 100mg tablet, 28 tablets


V1A10 Austell Losartan 100

R 14.9060 28 tablets 14 100 99.00 181936085 CO

Page 15 of 28


Item No





MOQ Total Score

NSN UOM

229 Magnesium chloride 500mg - 700mg slow release tablet, 60 tablets

Product awardedMagnesium Chloride 660mg tablet, 60 tablets

256 637 Mirren (Pty) Ltd V7149 Ultimag Tablets R 19.1200 60 tablets 14 100 90.00 180282649 CO

230 Mesalazine 400mg tablet, 90 tablets

25 349 Equity Pharmaceuticals (Pty) Ltd

V1QZ3 Asacol Tablets R 206.7500 90 tablets 14 20 90.00 189762990 CO

232 Metformin 500mg tablet,56 tablets


V1A10 Austell Metformin 500mg Tablets

R 8.3220 56 tablets 14 300 99.00 180670492 PG

232 Metformin 500mg tablet, 56 tablets




R 12.3550 84 tablets 14 240 99.00 180339480 PG


1 924 297 40% Mylan (Pty) Ltd V3PS6 Mylan Metformin 500mg

R 12.5000 84 tablets 14 10 96.94 180339480 PG


135 130 Mylan (Pty) Ltd V3PS6 Mylan Metformin 500mg

R 63.1600 500 tablets 14 1 98.00 189710513 CO





R 11.9700 60 tablets 14 420 99.00 180670494 PG


2 061 039 30% Mylan (Pty) Ltd V3PS6 Mylan metformin 850mg

R 12.8000 56 tablets 14 10 91.76 180670494 PG



R 18.1700 84 tablets 14 10 98.00 189711808 CO



R 62.7700 300 tablets 14 1 98.00 189710233 CO

239 Methyldopa 250mg tablet, 56 tablets

1 101 598 Pharmacare Limited V2205 Hy-Po-Tone 250mg Tabs 56

R 40.9716 56 tablets 14 25 95.00 189711810 CO

240 Methyldopa 250mg tablet, 84 tablets

1 030 009 Pharmacare Limited V2205 Hy-Po-Tone 250mg Tabs 84

R 56.5668 84 tablets 14 15 95.00 189710812 CO

242 Methylphenidate 10mg tablet, 30 tablets


VBVW2 Ritalin 10mg R 24.6200 30 tablets 14 1 93.00 189710452 CO

TO FOLLOW

TO FOLLOW

Page 16 of 28


Item No





MOQ Total Score

NSN UOM

243 Methylphenidate 20mg, modified release tablet/capsule, 30 tablets/capsules

Product AwardedMethylphenidate 20mg, modified release capsule, 30 capsules


VBVW2 Ritalin LA 20mg R 110.4700 30 capsules 14 1 93.00 181769645 CO

244 Methylphenidate 30mg, modified release tablet/capsule, 30 tablets/capsules

Product AwardedMethylphenidate 30mg, modified release capsule, 30 capsules


VBVW2 Ritalin LA 30mg R 183.9800 30 capsules 14 1 93.00 181769646 CO

245 Metoclopramide 10mg tablet, 10 tablets


V2272 Adco-Contromet 10mg 10's


95.00 181798176 PG



V2272 Adco-Contromet 10mg 100's


95.00 189711057 CO



V3LJ8 Clomax R 35.3400 500 tablets 14 72 95.00 189750564 CO

251 Midazolam 7,5mg tablet, 20 tablets


V2177 Dormicum 7.5mg R 77.6100 20 tablets 14 1 pack of 20 tablets

93.00 181751133 CO

252 Midazolam 15mg tablet, 20 tablets


V2177 Dormicum 15mg R 112.0000 20 tablets 14 1 pack of20 tablets

93.00 180190409 CO

254 Minoxidil 5mg tablet, 100 tablets


V2189 Loniten 5mg Tab, 100's

R 314.3300 100 tablets 14 1 93.00 189714350 CO

255 Minoxidil 10mg tablet, 100 tablets


V2189 Loniten 10mg Tab, 100's

R 550.0000 100 tablets 14 1 93.00 189714351 CO

256 Montelukast 4mg chewable tablet, 28 tablets


V1A08 Topraz 4 R 30.7800 28 tablets 14 5 90.00 181789304 CO

Page 17 of 28


Item No





MOQ Total Score

NSN UOM

257 Montelukast 5mg chewable tablet, 28 tablets



258 Montelukast 10mg tablet, 28 tablets



259 Morphine 10mg modified release tablet, 60 tablets


V0DM6 SRM Rhotard 10 R 127.1400 60 tablets 14 1 90.00 180105359 CO

260 Morphine 30mg modified release tablet, 60 tablets


V0DM6 SRM Rhotard 30 R 200.0200 60 tablets 14 1 90.00 180105391 CO

263 Nicotinamide 100mg tablet,28 tablets

336 074 Portfolio Pharmaceuticals (Pty) Ltd

VWB81 Portfolio Nicotinamide 100mg tablets

R 5.8400 28 tablets 14 1000 99.00 180339515 PG

264 Nicotinamide 100mg tablet, 84 tablets


VWB81 Portfolio Nicotinamide 100mg tablets

R 14.2200 84 tablets 14 84 99.00 181917398 CO

265 Nifedipine 5mg capsule, 100 capsules


VUV35 Bio-Nifedipine 5 Capsules 100's

R 34.3400 100 capsules 14 10 98.00 189710364 CO

266 Nifedipine 10mg capsule, 100 capsules


VUV35 Bio-Nifedipine 10mg Capsules 100's

R 55.7600 100 capsules 14 10 98.00 189710326 CO

267 Nifedipine 30mg modified release tablet, 28 tablets


VUV35 Bio Nifedipine XL 30 Tablets 30's

R 23.7000 30 tablets 14 400 x 30's 98.00 180012708 CO

268 Nifedipine 60mg modified release tablet, 28 tablets


VUV35 Bio Nifedipine XL 60 Tablets 30's

R 41.0000 30 tablets 14 320 x 30's 98.00 180012709 CO

270 Olanzapine 2,5mg tablet, 28 tablets


V1A08 Redilanz 2,5 R 18.2400 28 tablets 14 5 90.00 180959585 CO

271 Olanzapine 5mg tablet, 28 tablets

100 010 Mylan (Pty) Ltd V3PS6 Mylan Olanzapine 5mg

R 24.7300 30 tablets 14 30 98.00 181936077 CO

272 Olanzapine 10mg tablet, 28 tablets

189 976 Mylan (Pty) Ltd V3PS6 Mylan Olanzapine 10mg

R 30.9400 30 tablets 14 30 98.00 181936076 CO

273 Omeprazole 10mg dispersible tablet, 28 tablets


V2180 Losec Mups 10 R 41.1800 28 tablets 10 10 95.00 181778178 CO

Page 18 of 28


Item No





MOQ Total Score

NSN UOM

274 Omeprazole 10mg tablet/capsule, 28 tablets/capsules

Product AwardedOmeprazole 10mg capsule, 30 capsules


V1A08 Omez 10 R 17.6700 30 capsules 14 5 90.00 181936078 CO

276 Omeprazole 20mg capsule, 28 capsules

277 Orphenadrine 50mg tablet, 28 tablets.

2 962 888 Pharmacare Limited V2205 Phenerine 50mg Tabs 28

R 16.5414 28 tablets 14 60 95.00 180339583 CO

278 Orphenadrine 50mg tablet, 56 tablets

1 672 276 Pharmacare Limited V2205 Phenerine 50mg Tabs 56 B/B

R 32.3190 56 tablets 14 40 95.00 180339585 CO

279 Orphenadrine 50mg tablet, 84 tablets

478 352 Pharmacare Limited V2205 Phenerine 50mg Tabs 84 B/B

R 45.2580 84 tablets 14 20 95.00 180339586 CO

280 Oxazepam 10mg tablet, 100 tablets

84 137 Pharmacare Limited V2205 Serepax 10mg Tabs 100

R 38.0760 100 tablets 14 20 95.00 189712225 CO

281 Oxazepam 30mg tablet, 100 tablets

12 521 Pharmacare Limited V2205 Purata 30mg Tabs 100

R 51.0635 100 tablets 14 20 95.00 189714612 CO

282 Oxybutynin 5mg tablet, 84 tablets

Product AwardedOxybutynin 5mg tablet,Deviation: Pack Size:100 tablets


V2160 Ditropan R 39.9600 100 tablets 14 10 94.00 189710155 CO

283 Pancreatin 150mg equivalent to Amylase 8000 FIP units, Lipase 10000 FIP units and Protease 600 FIP units per capsule, 100 capsules

12 187 Abbott Laboratories (Pty) Ltd

V2150 Creon 10000 R 366.2820 100 capsules 14 1 unit of 100's 92.00 181747895 CO

284 Pancreatin 300mg equivalent to Amylase 18 000 FIP units, Lipase 25000 FIP units and Protease 1000 FIP units per capsule, 100 capsules

15 693 Abbott Laboratories (Pty) Ltd

V2150 Creon 25000 R 714.0618 100 capsules 14 1 unit of 100's 92.00 180231590 CO

TO FOLLOW

Page 19 of 28


Item No





MOQ Total Score

NSN UOM

285 Paracetamol 500mg tablet, 20 tablets


V2272 Adco-Napamol 20's


95.00 180155484 CO



VTS03 Painblok R 2.7100 20 tablets 14 900 80.56 180155484 CO

285 Paracetamol 500mg tablet,20 tablets


V1A10 Austell Paracetamol 500mg

R 2.8500 20 tablets 14 320 76.00 180155484 CO


9 296 813 11% Innovata Pharmaceuticals (Pty) Ltd

VBBL4 Painogesic R 2.8600 20 tablets 14 1200 74.61 180155484 CO


2 354 534 80% Innovata Pharmaceuticals (Pty) Ltd



588 633 20% Adcock Ingram Healthcare (Pty) Ltd

V2272 Adco-Napamol 100's


95.00 189753434 CO


307 078 Innovata Pharmaceuticals (Pty) Ltd


289 Perindopril 4mg tablet,28 tablets


VXZ32 Cipla Perindopril 4mg


294 Phenytoin 100mg capsule/tablet, 84 capsules/tablets

Product AwardedPhenytoin 100mg capsule, 84 capsules

2 491 511 Pharmacare Limited V2205 Phenytoin 100mg Caps 84

R 61.4688 84 capsules 14 20 95.00 189711804 CO

295 Phenytoin 100mg capsule/tablet, 100 capsules/tablets

Product AwardedPhenytoin 100mg capsule, 100 capsules


V2189 Epanutin 100mg Cap, 100's

R 85.5000 100 capsules 14 1 93.00 189715312 CO

298 Potassium chloride 600mg tablet, 100 tablets

748 243 Mirren (Pty) Ltd V7149 Ultipot R 54.0000 100 tablets 14 100 90.00 181917399 CO

Page 20 of 28


Item No





MOQ Total Score

NSN UOM

300 Pramipexole 0,25mg tablet, 100 tablets


VTS03 Oxpola 0.25mg R 159.6000 100 tablets 14 5 98.00 181758021 CO

302 Pravastatin 20mg tablet, 30 tablets


V2MB8 Pixeta 20mg R 19.9500 30 tablets 14 180 94.00 180230824 CO

312 Pregabalin 25mg capsule, 56 capsules


V2189 Lyrica 25mg Cap, 56's

R 83.0900 56 capsules 14 1 93.00 181842560 CO

313 Pregabalin 75mg capsule, 56 capsules


V2189 Lyrica 75mg Cap, 56's

R 83.0900 56 capsules 14 1 93.00 181831898 CO

316 Promethazine 10mg tablet, 100 tablets


V2160 Phenergan 10 R 14.1500 100 tablets 14 10 94.00 189710047 CO

317 Promethazine 25mg tablet, 100 tablets


V2160 Phenergan 25 R 21.8600 100 tablets 14 10 94.00 189710049 CO

319 Propranolol 10mg tablet, 50 tablets


V2180 Inderal 10 R 45.6000 50 tablets 10 10 95.00 189716004 CO

326 Pyridostigmine 10mg tablet, 50 tablets

23 100 Meda Pharma South Africa (Pty) Ltd

V2ZD6 Mestinon 10mg R 264.6700 50 tablets 90 10 90.00 180000607 CO

327 Pyridostigmine 60mg tablet, 150 tablets

18 617 Meda Pharma South Africa (Pty) Ltd

V2ZD6 Mestinon 60mg R 1 245.5200 150 tablets 90 10 90.00 189710277 CO

328 Pyridoxine (Vitamin B6) 25mg tablet, 28 tablets

8 079 902 65% Pharmachem Laboratories (Pty) Ltd

V3LA8 Egoli Pyridoxine 25mg tablets

R 2.4500 28 tablets 14 2000 85.68 180339610 CO


4 285 714 35% Portfolio Pharmaceuticals (Pty) Ltd

VWB81 Portfolio Vitamin 6 25mg tablets

R 2.2200 28 tablets 14 1000 99.00 180339610 CO




R 8.1900 100 tablets 14 75 99.00 189710278 CO

330 Quetiapine 25mg tablet, 100 tablets

7 671 Mylan (Pty) Ltd V3PS6 Mylan Quetiapine 25mg

R 50.1600 100 tablets 14 100 98.00 180350983 CO



R 101.5700 90 tablets 14 90 98.00 180351237 CO



R 119.1200 60 tablets 14 60 98.00 180351239 CO

Page 21 of 28


Item No





MOQ Total Score

NSN UOM



R 190.9400 60 tablets 14 60 98.00 181772178 CO

334 Quetiapine 50mg modified release tablet, 100 tablets

Product awardedQuetiapine 50mg modified release tabletDeviation: Pack Size: 60 tablets


V2180 Seroquel XR 50 R 166.5800 60 tablets 10 10 95.00 181867213 CO




V2180 Seroquel XR 200 R 283.9400 60 tablets 10 10 95.00 181867269 BT




V2180 Seroquel XR 300 R 330.9700 60 tablets 10 10 95.00 181867272 BT




V2180 Seroquel XR 400 R 399.4800 60 tablets 10 10 95.00 181867216 CO

338 Ranitidine 150mg tablet, 56 tablets


VUV35 Ranitidine 150 Biotech Tablets 60's

R 13.2000 60 tablets 14 200 x 60's 98.00 189712314 CO

339 Retinol (Vitamin A) 50 000iu snip-off, soft gel capsule, 50 capsules. Colour coded white (opaque)


VUV35 Vitaforce A50 000 IU Capsules 50's

R 28.9400 50 capsules 14 20 98.00 181798191 CO

Page 22 of 28


Item No





MOQ Total Score

NSN UOM

340 Retinol (Vitamin A) 100 000iu snip-off, soft gel capsule, 50 capsules. Colour coded blue (opaque)



R 37.2600 50 capsules 14 20 98.00 181798187 CO

341 Retinol (Vitamin A) 200 000iu snip-off, soft gel capsule, 50 capsules. Colour coded red (opaque)



R 54.8200 50 capsules 14 20 98.00 181798190 CO

342 Risperidone 0,5mg tablet, 28 tablets


V2MB8 Rispacor 0.5mg R 8.2100 30 tablets 14 50 94.00 181799554 CO

343 Risperidone 1mg tablet, 28 tablets


V2MB8 Rispacor 1mg R 4.7900 30 tablets 14 50 94.00 180339003 CO


1 157 261 Accord Healthcare (Pty) Ltd





346 Ropinirole 0,25mg tablet, 84 tablets


V2MB8 Accord Ropinirole 0,25mg

R 34.2000 84 tablets 14 12 94.00 181809452 CO

347 Ropinirole 0,5mg tablet,84 tablets


V2MB8 Accord Ropinirole 0,5mg

R 54.7200 84 tablets 14 12 94.00 181809456 CO

348 Ropinirole 1mg tablet, 84 tablets


V2MB8 Accord Ropinirole 1mg

R 83.2200 84 tablets 14 12 94.00 181809457 CO

349 Ropinirole 5mg tablet, 84 tablets


V2MB8 Accord Ropinirole 5mg

R 353.4000 84 tablets 14 12 94.00 181860070 CO

350 Senna extract equivalent to Sennosides A and B 13,5mg tablet, 20 tablets


VXZ32 Soflax Tablets R 5.0900 20 tablets 14 480 units 99.00 181826115 CO

351 Sevelamer 800mg tablet, 180 tablets

150 Sanofi-Aventis South Africa (Pty) Ltd

V2160 Renvela Tablets R 1 384.2200 180 tablets 14 10 94.00 181846974 CO

352 Sildenafil 20mg tablet, 90 tablets


V2189 Revatio 20mg Tab, 90s

R 2 256.1900 90 tablets 14 1 93.00 181828390 CO

Page 23 of 28


Item No





MOQ Total Score

NSN UOM



VXZ32 Sildenafil Cipla R 12.6100 4 tablets 14 10 units 99.00 180350988 CO


880 Pfizer Laboratories (Pty) Ltd

V2189 Avigra 100 R 49.2900 4 tablets 14 1 93.00 180350989 CO

355 Simvastatin 10mg tablet, 28 tablets


V1A10 Austell Simvastatin 10mg

R 5.9280 28 tablets 14 600 99.00 189762856 CO


5 740 464 40% Cipla Medpro South Africa (Pty) Ltd

VXZ32 Cipla-Simvastatin 10




V1A10 Austell Simvastatin 20mg

R 7.6950 28 tablets 14 600 99.00 189762970 CO

357 Spironolactone 25mg tablet, 28 tablets

1 614 762 Pharmacare Limited V2205 Spiractin 25mg Tabs 28

R 10.8300 28 tablets 14 80 95.00 181798184 CO


640 116 Sandoz SA (Pty) Ltd VVZ69 Spironolactone 25mg 56

R 20.8400 56 tablets 14 100 94.00 181747912 CO


38 068 Pharmacare Limited V2205 Spiractin 25mg Tabs 84

R 37.5972 84 tablets 14 20 95.00 181747914 CO


63 657 Sandoz SA (Pty) Ltd VVZ69 Spironolactone 25mg 200

R 76.2000 200 tablets 14 100 94.00 189710245 CO

361 Spironolactone 100mg tablet,60 tablets

11 420 Pharmacare Limited V2205 Spiractin 100mg Tabs 60

R 112.0050 60 tablets 14 10 95.00 189711050 CO

363 Sulfasalazine 500mg tablet, 100 tablets

Product AwardedSulfasalazine 500mg enteric coated tablet, 100 tablets


V2189 Salazopyrin EN 500mg Tab

R 236.4500 100 tablets 14 1 93.00 189714546 CO

364 Tamsulosin 0,4mg capsule, 28 capsules


VXZ32 Uromax R 21.4700 30 capsules 14 120 units 99.00 180318479 CO

Page 24 of 28


Item No





MOQ Total Score

NSN UOM

365 Theophylline 200mg modified release tablet, 56 tablets

1 995 297 Sandoz SA (Pty) Ltd VVZ69 Theophylline ANH 200mg 60

R 19.0400 60 tablets 14 100 94.00 189762882 CO

367 Theophylline 300mg modified release tablet, 56 tablets

220 639 Sandoz SA (Pty) Ltd VVZ69 Theophylline ANH 300mg 60

R 41.9800 60 tablets 14 100 94.00 189762886 CO

368 Thiamine (Vitamin B1) 100mg tablet, 28 tablets


VWB81 Portfolio Thiamine 100mg tablets

R 7.1300 28 tablets 14 1000 99.00 181798189 CO



V2272 Vit B1-100mg 28's R 7.3900 28 tablets 14 1 shipper (192 packs)

91.72 181798189 CO



VWB81 Portfolio Thiamine 100mg tablets

R 17.8800 84 tablets 14 1000 99.00 181917416 CO

370 Thyroxine sodium 0,025mg tablet, 28 tablets

2 575 Merck (Pty) Ltd V3018 Euthyrox 25ug R 3.5000 30 tablets 14 180 95.00 181934919 CO

372 Topiramate 25mg tablet, 56 tablets

42 343 Ranbaxy South Africa (Pty) Ltd

VVZ04 Toplep 25 R 25.0000 60 tablets 14 20 90.00 180208565 CO







375 Tramadol 50mg capsule/tablet, 20 capsules/tablets

Product AwardedTramadol 50mg capsule, 20 capsules


V1A10 Austell Tramadol 50mg

R 7.9800 20 capsules 14 500 99.00 180070238 CO


Product AwardedTramadol 50mg capsule, 100 capsules


V1A10 Austell Tramadol 50mg

R 31.9200 100 capsules 14 100 99.00 180155404 CO

Page 25 of 28


Item No





MOQ Total Score

NSN UOM


Product AwardedTramadol 100mg tablet, 60 tablets

99 113 Sandoz SA (Pty) Ltd VVZ69 Trama-Hexal SR 100mg 60 Tab FP

R 119.6600 60 tablets 14 100 94.00 181761190 CO


Product AwardedTramadol 200mg tablet, 60 tablets

27 340 Sandoz SA (Pty) Ltd VVZ69 Trama-Hexal SR 200mg 60 Tab FP

R 216.0200 60 tablets 14 100 94.00 181917410 CO

380 Tranexamic acid 500mg tablet,100 tablets


V2189 Cyklokapron T 500mg Tab

R 278.8700 100 tablets 14 1 93.00 189718982 CO

383 Ursodeoxycholic Acid 100mg tablet, 180 tablets


V2160 Ursotan R 766.3300 180 tablets 14 10 94.00 189715336 CO

385 Valproate sodium 100mg crushable tablet, 100 tablets


V2160 Epilim 100 Crushable

R 78.7500 100 tablets 14 10 94.00 181808859 CO

386 Valproate sodium 133,2mg and Valproic acid 58mg modified release tablet, 56 tablets


V2160 Epilim CR 200 R 27.0300 56 tablets 14 10 94.00 181813970 CO





1 001 066 Sanofi-Aventis South Africa (Pty) Ltd





Page 26 of 28


Item No





MOQ Total Score

NSN UOM

390 Valproate sodium 333mg and Valproic acid 145mg modified release tablet, 56 tablets



391 Valproate sodium 333mg and Valproic acid 145mg modified release tablet, 100 tablets



395 Venlafaxine 37,5mg tablet/capsule, 28 tablets/capsules

Product AwardedVenlafaxine 37,5mg capsule, 30 capsules


VXZ32 Venlor XR 37,5 R 39.1700 30 capsules 14 30 99.00 181851983 CO

396 Venlafaxine 75mg tablet/capsule, 28 tablets/capsules

Product AwardedVenlafaxine 75mg capsule, 30 capsules


VXZ32 Venlor XR 75 R 39.1700 30 capsules 14 60 99.00 180358280 CO

397 Venlafaxine 150mg tablet/capsule, 28 tablets/capsules

Product AwardedVenlafaxine 150mg capsule, 30 capsules


VXZ32 Venlor XR 150 R 68.5000 30 capsules 14 60 99.00 180358282 CO

398 Verapamil 40mg tablet, 84 tablets

185 030 Pharmacare Limited V2205 Vasomil 40mg Tabs 84

R 32.1500 84 tablets 14 30 95.00 180339609 CO

400 Verapamil 240mg tablet, 28 tablets

39 213 Sandoz SA (Pty) Ltd VVZ69 Vera-Hexal 240mg SR 30

R 52.6700 30 tablets 14 100 94.00 189709075 CO

401 Vigabatrin 500mg tablet, 100 tablets


V2160 Sabril R 897.3700 100 tablets 14 10 94.00 180115255 CO

402 Vit. B6 (Pyridoxine HCl) 25mg tablet, 500 tablets



R 37.2400 500 tablets 14 75 99.00 189710353 CO

Page 27 of 28


Item No





MOQ Total Score

NSN UOM

403 Vitamin B co: Vit. B1 (Thiamine HCL) 5mg, Vit. B2 (Riboflavine) 2mg, Vit. B6 (Pyridoxine HCL) 2mg and Nicotinamide 20mg tablet, 28 tablets

14 966 645 68% Pharmachem Laboratories (Pty) Ltd

V3LA8 Egoli Vitamin B Complex Strong tablets

R 1.6500 28 tablets 14 1600 95.00 180339611 CO

403 Vitamin B co: Vit. B1 (Thiamine HCL) 5mg, Vit. B2 (Riboflavine) 2mg, Vit. B6 (Pyridoxine HCL) 2mg and Nicotinamide 20mg


VWB81 Portfolio Vitamin B Co Strong tablets

R 1.6600 28 tablets 14 1000 98.45 180339611 CO

405 Warfarin 5mg tablet, 100 tablets

397 888 Pharmacare Limited V2205 Aspen Warfarin 5mg Tabs 100

R 68.3658 100 tablets 14 15 95.00 189759084 CO

406 Zinc tablet, scored, dispersible, equivalent to elemental zinc 20mg, 10 tabletsMCC registerd

214 808 Zinplex Marketing CC V22Z6 Zinplex Soluble Tablets


407 Zinc tablet, scored, dispersible, equivalent to elemental zinc 20mg, 100 tabletsMCC registerd

50 320 Zinplex Marketing CC V22Z6 Zinplex Soluble Tablets


Page 28 of 28

0

Special Requirements and Conditions of Contract

HP09–2016SD

THE SUPPLY AND DELIVERY OF SOLID DOSAGE FORMS TO THE DEPARTMENT OF HEALTH

FOR THE PERIOD 01 AUGUST 2016 TO 31 JULY 2018

VALIDITY PERIOD: 120 days

National Department of Health

Compulsory Briefing Session 09 February 2016 Time: 9:00–11:00

Venue: National Department of Health

Civitas Building, Impilo Board Room, North Tower, Podium Level

242 Struben Street (Cnr Thabo Sehume and Struben streets), Pretoria

SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT HP09–2016SD

Page | 1 of 3

INDEX SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT ............................................. 2

1. BACKGROUND .................................................................................................................... 2

2. EVALUATION CRITERIA: ................................................................................................... 2

2.1. PREFERENCE POINTS SYSTEM .................................................................................... 2

2.2. PREFERENCE FOR LOCAL MANUFACTURERS ......................................................... 3

3. PARTICIPATING AUTHORITIES ....................................................................................... 4

3.1. POST AWARD PARTICIPATION ....................................................................................... 4

4. CONTRACT PERIOD .......................................................................................................... 4

5. CENTRAL SUPPLIER DATABASE (CSD) ....................................................................... 5

6. DOCUMENT SUBMISSION AND COMPLETION FOR BIDDING ................................ 5

6.1. BID DOCUMENTS FOR SUBMISSION ............................................................................ 5

6.2. COMPLETION OF DOCUMENTS AND BID SUBMISSION .......................................... 6

7. TAX CLEARANCE CERTIFICATE ..................................................................................... 7

8. LEGISLATIVE REQUIREMENTS AND AUTHORISATION DECLARATION ............. 7

8.1. LEGISLATIVE REQUIREMENTS ...................................................................................... 7

8.2. DECLARATION OF AUTHORISATION ............................................................................ 8

9. BIDDING PROCESS ADMINISTRATION ......................................................................... 8

10. COUNTER CONDITIONS ................................................................................................... 9

11. PROHIBITION OF RESTRICTIVE PRACTICES ............................................................. 9

12. FRONTING .......................................................................................................................... 10

13. PRODUCT COMPLIANCE ................................................................................................ 10

13.1. SUBMISSION OF SAMPLES ........................................................................................... 10

14. PRODUCT AWARD ........................................................................................................... 11

14.1. AWARD CONDITIONS ...................................................................................................... 11

14.2. SPLIT AND MULTIPLE AWARDS ................................................................................... 11

14.3. PRE AWARD SUPPLIER DUE DILIGENCE .................................................................. 12

15. PRICE QUALIFICATION ................................................................................................... 12

16. PRICE REVIEW .................................................................................................................. 13

16.1. ELIGIBILITY RELATING TO RATE OF EXCHANGE ADJUSTMENTS ..................... 13

16.2. INSTRUCTIONS FOR PRICE BREAKDOWN ............................................................... 13

16.3. PRICE ADJUSTMENTS RELATING TO FOREIGN EXCHANGE RISK ................... 14

APPLICATION FOR CONTRACTUAL PRICE ADJUSTMENTS ................................................ 15

ROUTINE PRICE ADJUSTMENTS ................................................................................................. 15


Page | 2 of 3

EXCEPTIONAL PRICE ADJUSTMENTS ....................................................................................... 15

16.4. PRICE ADJUSTMENTS BASED ON A SYSTEMATIC REVIEW ............................... 16

17. ORDERS, DELIVERY AND CONTINUITY OF SUPPLY .............................................. 16

17.1. ORDERS .............................................................................................................................. 16

17.2. DELIVERIES ........................................................................................................................ 17

17.3. CONTINUITY OF SUPPLY ............................................................................................... 18

18. PACKAGING AND LABELLING ....................................................................................... 19

18.1. PACKAGING ....................................................................................................................... 19

18.2. LABELLING ......................................................................................................................... 20

18.3. BARCODES ......................................................................................................................... 20

19. QUALITY .............................................................................................................................. 21

20. SHELF-LIFE ........................................................................................................................ 21

21. POST AWARD .................................................................................................................... 21

21.1. MONITORING ..................................................................................................................... 21

21.2. REPORTING ....................................................................................................................... 22

21.3. CEDING, MERGERS, TAKE OVERS AND CHANGES IN SUPPLIER DETAILS ... 23

21.4. THIRD PARTIES ................................................................................................................. 23

21.5. CONTACT DETAILS .......................................................................................................... 23

22. ABBREVIATIONS ............................................................................................................... 24


Page | 2 of 24

SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT

1. BACKGROUND

This bidding process, and all contracts emanating therefrom, will be subject to the

General Conditions of Contract issued in accordance with Treasury Regulation 16A

published in terms of the Public Finance Management Act, 1999 (Act 1 of 1999). The

Special Requirements and Conditions of Contract are supplementary to the General

Conditions of Contract. Where the Special Requirements and Conditions of Contract

are in conflict with the General Conditions of Contract, the Special Requirements and

Conditions of Contract will prevail.

2. EVALUATION CRITERIA:

2.1. PREFERENCE POINTS SYSTEM

2.1.1. In terms of Regulation 6 of the Preferential Procurement Regulations, published in

terms of the Preferential Procurement Policy Framework Act, 2000 (Act 5 of 2000),

responsive bids will be adjudicated on the basis of the 90/10-preference point

system in terms of which points are awarded to bidders on the basis of:

The bid price (final delivered price including VAT): maximum 90 points

B-BBEE status level of bidder: maximum 10 points

2.1.2. The following formula will be used to calculate the points for price:

90 1

Where:

Ps= Points scored for comparative price of bid under consideration

Pt= Comparative price of bid under consideration

Pmin= Comparative price of lowest acceptable bid

2.1.3. A maximum of 10 points may be allocated to a bidder for attaining their B-BBEE

status in accordance with the table below:

B-BBEE Status Level of Contributor Number of Points

1 10 2 9 3 8 4 5 5 4 6 3


Page | 3 of 24

B-BBEE Status 7 2 8 1

Non-compliant contributor 0

2.1.4. Bidders are required to complete the preference claim form (SBD 6.1) irrespective of

whether B-BBEE status level points are claimed or not.

2.1.5. Only bidders who have completed and signed the declaration part of the preference

claim form, and who have submitted a B-BBEE status level certificate issued by a

registered auditor, accounting officer (as contemplated in section 60(4) of Close

Corporation Act, 1984 (Act 69 of 1984)) or an accredited verification agency will be

considered for preference points.

2.1.6. Bidders that fail to comply with paragraphs 2.1.4 and 2.1.5 will be allocated zero

points for B-BBEE status.

2.1.7. The points scored by a bidder for B-BBEE contribution will be added to the points

scored for price.

2.1.8. The points scored will be rounded off to the nearest 2 decimal points.

2.1.9. The National Department of Health may, before a bid is adjudicated or at any time,

require a bidder to substantiate claims it has made with regard to preference points.

2.1.10. In the event that two or more bids have scored an equal number of total points, the

contract will be awarded to the bidder scoring the highest number of points for B-

BBEE. Should two or more bids be equal in all respects, the award shall be decided

by the drawing of lots.

2.1.11. A contract may, on reasonable and justifiable grounds, be awarded to a bid that did

not score the highest number of points.

2.2. PREFERENCE FOR LOCAL MANUFACTURERS

2.2.1. The Department may give preference to pharmaceutical manufacturers who

formulate and/or package products in South Africa as specified by the Department of

Trade and Industry. This list of specified products may be published on the National

Department of Health website, www.health.gov.za.

2.2.2. In the event that a list of designated items is published, these may be awarded to

local pharmaceutical manufacturers, provided such an award does not impact upon

security of supply and/or affordability.

2.2.3. Bids for products that qualify for preference, must comply with all of the following

criteria:


Page | 4 of 24

The site/s of manufacture and/or packaging for the product offered is located in

South Africa;

The Medicine Registration Certificate, issued by the Medicines Control Council,

or its successor in title, in terms of the Medicines and Related Substances Act,

Act 101 of 1965, as amended, includes the proposed South African

manufacturer and/or packer site/s;

Where there are alternative offers, the reference price as published by National

Department of Health has not been exceeded;

Bids are within 10% of the highest points scored for the item;

Previous supplier performance;

Compliance to all other provisions contained in these Special Requirements and

Conditions of Contract.

3. PARTICIPATING AUTHORITIES The National Department of Health and the following Provincial Departments of

Health will participate in this contract: Eastern Cape, Free State, Gauteng,

KwaZulu-Natal, Limpopo, Mpumalanga, Northern Cape, North West and Western

Cape.

3.1. POST AWARD PARTICIPATION

Regulation 16A6.6 of the Treasury Regulations for Departments, Trading Entities,

Constitutional Entities and Public Entities, issued in terms of the Public Finance

Management Act, 1999, (Act 1 of 1999), states that the Accounting

Officer/Accounting Authority may, on behalf of a department, constitutional

institution or public entity, request to participate in any contract arranged by means

of a competitive bidding process by any organ of state, subject to the written

approval of such organ of state and the relevant contractors. The Participating

Authorities on this contract may therefore be extended in terms of this Regulation.

4. CONTRACT PERIOD

The contract period shall commence on 01 August 2016 and expire on 31 July

2018.


Page | 5 of 24

5. CENTRAL SUPPLIER DATABASE (CSD)

5.1. The Central Supplier Database (CSD) is managed by National Treasury to serve as

the source of all supplier information for all spheres of government. The purpose of

centralising government’s supplier database is to reduce duplication of effort and

cost for both supplier and government while enabling electronic procurement

processes.

5.2. It is a compulsory requirement that all bidders be registered on the CSD at the

closing time of the bid (date and hour specified in the bidding documents).

Furthermore, suppliers must provide the unique supplier number and security code

allocated to them as part of the bid document.

5.3. The bid will be deemed non-responsive if the bidder fails to provide the unique

supplier number and security code.

5.4. For information regarding registration on the CSD, go to www.csd.gov.za.

6. DOCUMENT SUBMISSION AND COMPLETION FOR BIDDING

6.1. BID DOCUMENTS FOR SUBMISSION

6.1.1. Bidders MUST submit the following completed and signed documents in the Bid

Pack:

SBD1: Invitation to bid

SBD4: Declaration of Interest

SBD5: The National Industrial Participation Programme

SBD6.1: Preference points claim form in terms of the Preferential Procurement

Regulations 2011

SBD8: Declaration of bidder's past supply chain management practices

SBD9: Certificate of independent bid determination

PBD1: Authorisation Declaration (if applicable)

PBD4.1: Supplier details

PBD5: Declaration of Compliance with Good Manufacturing Practice (GMP)

PBD7: Compulsory briefing session attendance certificate

Bid Response Document: Completion of all response fields per item offered is

mandatory.

B-BBEE Status Level Verification Certificate (where preference points are

claimed) (Original or Certified Copy)


Page | 6 of 24

A certified copy of the license to manufacture, including all annexures, issued by

the Medicines Control Council, or its successor in title, in terms of the Medicines

and Related Substances Act, Act 101 of 1965, as amended.

Certified copy of the Medicine Registration Certificate (GW12/7) with all the

associated conditions, issued by the Medicines Control Council, or its successor

in title, in terms of the Medicines and Related Substances Act, Act 101 of 1965,

as amended.

Copy of the package insert approved by the Medicines Control Council, or its

successor in title, for each product offered. Each package insert must be in A4

format.

6.2. COMPLETION OF DOCUMENTS AND BID SUBMISSION

6.2.1. Bidders are required to submit three sets of bid documents according to the

instructions below.

6.2.2. Set 1: Hard copy (constitutes the legally binding bid document)

All SBD, PBD and Bid Response forms must be typewritten in black ink. Where no

electronic entry field is provided bidders must complete the forms in black ink,

handwritten in capital letters. The signed hard copy of the bid document will serve

as the legal bid document. Bidders must submit their complete bid in hard copy

format (paper document).

The Chief Executive Officer, Chief Financial Officer, or authorised designee of the

entity submitting the bid must attach his/her official signature where indicated on

the documents. All pages in the bid submission must be initialled by the same

person with black ink. The use of correction fluid is not acceptable. Any change/s

must be clearly indicated and initialled.

6.2.3. Set 2: Scanned version of Set 1. (i.e. Scanned complete hard copy)

Bidders must submit a PDF version of the entire signed hardcopy bid, including all

certificates and documents requested.

6.2.4. Set 3: Electronic version of bid documents

Bidders must submit the electronic versions of all bidding documents to facilitate

data extraction. The PDF document must be submitted as editable PDF and the

Bid Response Document in Excel (not PDF).

6.2.5. Set 2 and Set 3 must be included on a CD and submitted in a sealed package with

Set 1. The full name and address of the bidder, including the return address of the

bidder, the bid number and the closing date of the bid must be clearly indicated on

the package. All fields must be completed. Where information requested is not

relevant this should be indicated with N/A.


Page | 7 of 24

6.2.6. All three sets must be submitted before the closing time of the bid (date and hour

specified in the bidding documents).

6.2.7. All three sets of information must be submitted in order for the bid to be deemed

complete. Incomplete bids will be deemed non-responsive.

7. TAX CLEARANCE CERTIFICATE

Bidders will not be required to provide an original valid tax clearance certificate to

departments as part of the documents for this bid. In any circumstances where the

CSD encounters challenges, the Department reserves the right to request the

provision of a valid tax clearance certificate which must be provided within ten days

of request.

8. LEGISLATIVE REQUIREMENTS AND AUTHORISATION

DECLARATION

8.1. LEGISLATIVE REQUIREMENTS

8.1.1. All medicines offered by bidders must be registered in terms of section 15 of the

Medicines and Related Substances Act, Act 101 of 1965, as amended. The

medicines must comply with the conditions of registration for the duration of the

contract.

8.1.2. For all offered products, the bidder must be indicated as the applicant on the

Medicine Registration Certificate GW12/7, issued in terms of section 15(3)(a) of

the Medicines and Related Substances Act, Act 101 of 1965, as amended.

8.1.3. In exceptional circumstances the National Department of Health may accept bids

from bidders who are not indicated as the applicant on the Medicine Registration

Certificate. The decision to consider such bids will be made on a case-by-case

basis.

8.1.4. In the event of a bidder not being the applicant, all details of the agreement

between the bidder and the applicant must be disclosed as per paragraph 9.2 of

the Special Requirements and Conditions of Contract and the Authorisation

Declaration (PBD1) forms submitted.

8.1.5. The bidder offering a product must be the holder of a licence to manufacture

medicines in terms of section 22C(1)(b) of the Medicines and Related Substances

Act, Act 101 of 1965, as amended.

8.1.6. Bidders must comply with the requirements of the Patents Act, 1978 (Act 57 of

1978) and the Trade Marks Act, 1993 (Act 194 of 1993) as amended. Where

applicable, an explanation for non-compliance must be provided.


Page | 8 of 24

8.2. DECLARATION OF AUTHORISATION

8.2.1. Only the holder of a certificate of registration in terms of the Medicines and Related

Substances Act, Act 101 of 1965, as amended may submit a bid.

8.2.2. In the event that the Manufacturer, Packer or other, as listed on the medicine

registration certificate, are external, third parties the bidder must ensure that all

legal, financial and supply arrangements have been mutually agreed upon

between the bidder and these third parties.

8.2.3. Where third parties are involved the bidder must submit a duly completed and

signed Authorisation Declaration (PBD1). Failure to submit the full declaration will

invalidate the bid for such goods offered.

8.2.4. The National Department of Health reserves the right to verify any information

supplied by the bidder in the Authorisation Declaration at any time. Should the

information be found to be false or incorrect, the National Department of Health will

exercise any of the remedies available to it in order to disqualify the bid, or cancel

the contract, if already awarded.

8.2.5. No agreement between the bidder and a third party will be binding on the National

Department of Health or Participating Authorities.

8.2.6. Accountability with regard to meeting the conditions of any contract emanating

from this bidding process rests with the successful bidder and not any third party.

9. BIDDING PROCESS ADMINISTRATION

9.1. All communication between the bidder and the National Department of Health must

be in writing and addressed to the Director: Affordable Medicines.

9.2. The Affordable Medicines Directorate within the National Department of Health is

responsible for managing the bidding process and will communicate with bidders to

request extension of the validity period of the bid, should it be necessary.

9.3. Any unsolicited communication between the closing date and the award of the

contract between the bidder and any government official or a person acting in an

advisory capacity for the National Department of Health in respect to any bids, is

discouraged.


Page | 9 of 24

10. COUNTER CONDITIONS

Any amendments to any of the bid conditions, changes to bid specifications or

setting of any other counter conditions by bidders will result in the invalidation of

such bids.

11. PROHIBITION OF RESTRICTIVE PRACTICES

11.1. In terms of section 4(1) of the Competition Act, Act 89 of 1998, as amended, an

agreement between, or concerted practice by, firms, or a decision by an association

of firms, is prohibited if it is between parties in a horizontal relationship and if a

bidder(s) is/are or a contractor(s) was/were involved in:

directly or indirectly fixing a purchase or selling price or any other trading

condition;

dividing markets by allocating customers, suppliers, territories or specific types

of goods or services; or

collusive bidding.

11.2. Section 4(2) of Act 89 of 1998 states that an agreement to engage in a restrictive

horizontal practice referred to in subsection (1)(b) of the Act is presumed to exist

between two or more firms if:

any one of those firms owns a significant interest in the other, or they have at

least one director or substantial shareholder in common; or

any combination of those firms engages in that restrictive horizontal practice.

11.3. If a bidder or contracted supplier, in the judgement of the purchaser, has engaged in

any of the restrictive practices referred to above, the purchaser may refer the matter

to the Competition Commission for investigation and possible imposition of

administrative penalties as contemplated in the Competition Act 89 of 1998.

11.4. If a bidder or contracted supplier has been found guilty by the Competition

Commission of any of the restrictive practices referred to above, the purchaser may,

in addition and without prejudice to any other remedy provided for, invalidate the bid

for such item(s) offered, and/or terminate the contract in whole or part, and/or

restrict the bidder or contracted supplier from conducting business with the public

sector for a period not exceeding ten (10) years and/or claim damages from the

bidder or contracted supplier concerned.


Page | 10 of 24

12. FRONTING

12.1. The Department of Health supports the spirit of broad-based black economic

empowerment and recognises that real empowerment can only be achieved through

individuals and businesses conducting themselves in accordance with the

Constitution and in an honest, fair, equitable, transparent and legally compliant

manner. Against this background the Department of Health condemns any form of

fronting.

12.2. The National Department of Health may, as part of the bid evaluation processes,

conduct or initiate the necessary enquiries/investigations to determine the accuracy

of the representation made in bid documents. Should any of the fronting indicators

as contained in the Guidelines on Complex Structures and Transactions and

Fronting, issued by the Department of Trade and Industry, be established during

such enquiry/investigation, the onus will be on the bidder/contractor to prove that

fronting does not exist. Failure to do so within a period of 14 days from date of

notification may invalidate the bid/contract and may also result in the restriction of the

bidder/contractor to conduct business with the public sector for a period not exceeding

ten years, in addition to any other remedies the National Treasury may have against

the bidder/contractor concerned.

13. PRODUCT COMPLIANCE

Prior to award products will be evaluated for:

Compliance with specifications as set out in the Bid Response Document.

Registration of product in terms of the Medicines and Related Substances Act,

Act 101 of 1965, as amended.

Availability of samples at both sample evaluation sites as detailed in paragraph

13.1.

13.1. SUBMISSION OF SAMPLES

13.1.1. Samples must be submitted to each of the addresses indicated below, prior to

closing date and time of bid:

Mr Dumisani Malele Mr Nisaar Mia Depot Manager Pharmaceutical Policy Specialist Tel: 011 628 9001 Tel: 021 483 5800 Gauteng: Medical Supplies Depot Western Cape: Department of Health Transito In Pharmaceutical Services 35 Plunkett Avenue 4 Dorp Street Room 10-07 Hurst Hill Cape Town 2092 8001


Page | 11 of 24

13.1.2. No samples must be sent to the Directorate: Affordable Medicines at the National

Department of Health.

13.1.3. Samples must be marked with the bid number, the item number as well as the

bidder’s name and address.

13.1.4. Bidders must submit at least one original pack of each offer for evaluation.

13.1.5. Bids where samples are not submitted to both facilities listed in paragraph 13.1.1,

will not be considered for award.

13.1.6. It is the responsibility of the bidder to ensure that samples have been received at

the addresses provided.

13.1.7. All samples for awarded items will be retained for the period of the contract.

13.1.8. All samples must be a true representation of the product which will be supplied.

13.1.9. All samples submitted must be inclusive of the MCC approved package insert.

13.1.10. In the case of schedule 6 items, only an empty original package and the MCC

approved package insert must be submitted and NOT the content of the package.

14. PRODUCT AWARD

14.1. AWARD CONDITIONS

14.1.1. The National Department of Health reserves the right not to award a line item.

14.1.2. The National Department of Health reserves the right to negotiate prices.

14.1.3. In cases where the tender does not achieve the most economically advantageous

price, the National Department of Health reserves the right not to award that item.

14.1.4. Pack sizes suitable for a 28-day treatment cycle are required. Should a 30-day

pack size be offered, no conversion factor will be applied. Direct comparisons will

be made between 28 and 30-day pack sizes during evaluation.

14.1.5. The Department of Health may change treatment protocols and/or product

formulations where required, due to emerging clinical evidence, disease profiles,

safety or resistance patterns. In these circumstances, the National Department of

Health reserves the right to cancel the contract for an item or a vary the quantity

awarded based on expected changes in projected demand. In these instances, the

Department of Health will notify the contracted supplier within a reasonable time of

the expected change. However, in cases where patient safety is a concern, these

changes may be implemented with immediate effect.

14.2. SPLIT AND MULTIPLE AWARDS

14.2.1. The National Department of Health reserves the right to issue split or multiple

awards, where necessary, to ensure security of supply.


Page | 12 of 24

14.2.2. The following will be taken into consideration when contemplating a split award:

Source of API and manufacturing site.

Capacity to meet expected demand as per published estimates in the Bid

Response Document.

Estimated volume to be supplied.

Risk to public health if the item is not available.

Past compliance of the bidder with contractual obligations.

14.2.3. Two-way split awards will be made in accordance with the following schedule

based on the points scored:

Category Difference between points

scored

Recommended percentage

split

A Equal points 50/50

B < 5 points 60/40

C >5-10 points 70/30

D >10-20 points 80/20

E >20 points 90/10

14.2.4. Where a split for more than 2 suppliers is contemplated, the following formula will

used to allocate volumes for award:

For a three way split: Supplier share = 33.3% + (supplier score - mean score) x

2.3%

For a four way split: Supplier share = 25% + (supplier score - mean score) x 2%

14.3. PRE AWARD SUPPLIER DUE DILIGENCE

The National Department of Health reserves the right to conduct supplier due

diligence prior to the final award of contract. Supplier capacity may be assessed

based on past compliance of the bidder with contractual obligations and

manufacturing capacity as declared by the bidder.

15. PRICE QUALIFICATION

15.1. Bidders must quote a final price inclusive of delivery and Value Added Tax (VAT).

15.2. If a price exclusive of VAT is submitted the bid will be deemed non-responsive.

15.3. The bid price offered for a product is deemed to be for the pack size as advertised

in the item specification.

15.4. Prices submitted must not exceed the Reference Price as published.


Page | 13 of 24

15.5. Prices submitted must not exceed the ex manufacturer component of the Single

Exit Price.

15.6. Prices submitted for this bid will be regarded as firm and subject only to review in

terms of Paragraph 16.

15.7. Bidders are advised to refer to the Reference Price List for HP09-2016SD

published on the National Department of Health website (www.health.gov.za)

before preparing the bid submission.

16. PRICE REVIEW

The National Department of Health envisages three types of price review processes

for the duration of this contract:

A routine adjustment to mitigate foreign exchange fluctuations;

An exceptional adjustment to mitigate significant short-term foreign exchange

fluctuations; and

A systematic review of prices for comparable products available in the

international market place.

16.1. ELIGIBILITY RELATING TO RATE OF EXCHANGE ADJUSTMENTS

16.1.1. Eligibility for price adjustments relating to foreign exchange risk depends on:

The submission of a complete price breakdown per instructions below for all

relevant products; and

Assessment of the rationality of this price breakdown by the National

Department of Health.

16.2. INSTRUCTIONS FOR PRICE BREAKDOWN

16.2.1. The price breakdown must be completed on the signed bid response document as

well as the electronic version. The delivered price must be divided across five

components:

1. Active Pharmaceutical Ingredients (API); 2. Formulation; 3. Packaging; 4. Logistics; 5. Gross margin (remaining portion).

16.2.2. The sum of these categories must be equal to 100% of the delivered price for the

line item.

16.2.3. The local + imported portions of the first three components must add up to 100%

within each component (e.g. Portion of API attributable to local + Portion of API

attributable to import = 100% of specific API component).


Page | 14 of 24

16.2.4. VAT must be apportioned equally across all components and not regarded as a

separate component.

16.2.5. Labour must be apportioned appropriately across the relevant components.

16.2.6. Breakdown must be in percentage format to the closest whole percentage (e.g.

20%).

16.2.7. The National Department of Health reserves the right to engage with bidders to

verify any of the components of the bid price, which may include audit of invoices

and related documentation.

16.3. PRICE ADJUSTMENTS RELATING TO FOREIGN EXCHANGE RISK

16.3.1. Only the portion of the bid price facing foreign exchange risk will be adjusted. This

portion is determined by the price breakdown on the signed bid submission.

16.3.2. Adjustments are always calculated using the original awarded contracted price as

the base.

16.3.3. Price adjustments relating to foreign exchange will be based on the percentage

change between the relevant base average rate of exchange (RoE) and an

adjustment average RoE. Rates are sourced from the Reserve Bank

(www.resbank.co.za).

16.3.4. Eligibility for favourable Contractual Price Adjustments may be withdrawn in light of

evidence of poor compliance with contractual obligations.

16.3.5. Base average RoE for this tender will be as follows, per currency:

Currency Base Average Rates of Exchange for the period 01 August 2015 to

28 January 2016 Rand per US Dollar R 14.2193 Rand per Br Pound R 21.5151

Rand per Euro R 15.6583

Yuan Renminbi per Rand CN¥ 0.4530

Indian Rupee per Rand I ₹ 4.6702

16.3.6. Should the bidder make use of any currency not mentioned above, the bidder must

stipulate this clearly and submit the calculated average RoE for the period 01

August 2015 to 28 January 2016 using the South African Reserve Bank published

rates for the specific currency.


Page | 15 of 24

APPLICATION FOR CONTRACTUAL PRICE ADJUSTMENTS

16.3.7. Scanned copies of signed applications for price adjustments must be received by

the National Department of Health prior to the submission dates detailed in the

tables below.

16.3.8. Where no application for an adjustment relating to foreign exchange has been

received and such an adjustment would be favourable to the Department, this will

be implemented automatically.

16.3.9. Foreign exchange adjustments may never result in a price exceeding the current

Single Exit Price, ex Logistics.

ROUTINE PRICE ADJUSTMENTS

16.3.10. Schedules for routine price reviews, and periods for calculating adjustment

average RoE, are detailed in the table below:

Review Period for calculating adjustment average RoE

Submission of request for price review to reach the

office by

Date from which adjusted prices will become

effective 1 1 July2016 –

31 December 2016 03 January 2017 1 February 2017

2 1 January 2017 – 30 June 2017

03 July 2017 1 August 2017

3 1 July 2017 – 31 December 2017

03 January 2018 1 February 2018

EXCEPTIONAL PRICE ADJUSTMENTS

16.3.11. Suppliers may request exceptional price adjustments according to the schedule in

the table below. These will be activated if the absolute change between the base

RoE and the three month retrospective average RoE indicated in the table below

fluctuates by more than 10%.



office by


effective 0.1 01 July 2016 –

30 September 2016 03 October 2016 01 November 2016

1.1 1 January 2017 – 31 March 2017

03 April 2017 01 May 2017

2.1 01 July 2017 – 30 September 2017

03 October 2017 01 November 2017

3.1 01 January 2018 – 31 March 2018

03 April 2018 01 May 2018


Page | 16 of 24

16.3.12. Suppliers who received exceptional adjustments will receive routine adjustments

based on the preceding three months, rather than the usual six month historical

average exchange rate. The periods for calculating adjustment average RoE in

these instances are detailed in the table below:


post exceptional adjustment


office by


effective

1 1 October 2016 – 31 December 2016


2 1 April 2016 – 30 June 2017

03 July 2017 1 August 2017

3 1 October 2017 – 31 December 2017


16.4. PRICE ADJUSTMENTS BASED ON A SYSTEMATIC REVIEW

16.4.1. The National Department of Health reserves the right to review international prices

to identify lowest comparable global prices.

16.4.2. Where this review identifies any prices that are lower than contract prices the

National Department of Health will enter into price negotiations with the contracted

supplier.

16.4.3. Where the outcome of this negotiation is deemed unfavourable, the National

Department of Health reserves the right to terminate the award for the item in

question.

17. ORDERS, DELIVERY AND CONTINUITY OF SUPPLY

17.1. ORDERS

17.1.1. The quantities reflected in the advertised bid response document are estimated

volumes and are not guaranteed.

17.1.2. Fluctuations in monthly demand may occur.

17.1.3. Successful bidders will be informed of estimates specific to Participating

Authorities upon award.

17.1.4. Contracted suppliers and Participating Authorities are responsible for reviewing

these estimated quantities on a monthly basis in order to determine and commit to

a rolling quarterly demand plan, thus improving predictability of demand.

17.1.5. Proposed minimum order quantities should facilitate delivery directly to facilities.

The National Department reserves the right to negotiate minimum order quantities

where necessary. Where consensus regarding minimum order quantities cannot be

reached the bid may not be awarded.


Page | 17 of 24

17.1.6. In order to facilitate efficient implementation of the direct delivery strategy

contracted suppliers must pack orders by facility as per the purchase order.

17.1.7. Only orders made using an official, authorised purchase order format are valid.

17.1.8. Suppliers are required to acknowledge receipt of all purchase orders received from

participating authorities, in a manner stipulated by the relevant participating

authority.

17.1.9. Changes to any quantities ordered may only be made upon receipt of an amended

purchase order.

17.1.10. The Participating Authorities reserve the right to cancel orders where the lead time

exceeds the delivery lead time specified in the contract (as per paragraph 17.2 of

the Special Requirements and Conditions of Contract) and may at their discretion

purchase supplies of a similar quality and up to the same quantity in substitution of

the goods not supplied in conformity with the contract (as per paragraph 21.6 of

the General Conditions of Contract).

17.1.11. In cases where an order is received which appears to be irrational or misaligned

with estimates, the contracted supplier must liaise with the relevant Participating

Authority prior to processing the order.

17.2. DELIVERIES

17.2.1. The initial lead time as proposed in the bid response document will be calculated

from date of award of the contract and NOT the date of placement of the first order.

This period may not exceed 75 calendar days from the date of award.

17.2.2. Lead-time within the contract period is defined as the time from submission of

order to supplier to time of receipt by the Department as confirmed by the Proof of

Delivery document. This lead-time may not exceed 14 calendar days.

17.2.3. Failure to comply with the contractual lead-time will result in penalties being

enforced as per paragraph 21 and 22 of the General Conditions of Contract.

17.2.4. Products and related documentation must be delivered in accordance with the

terms, conditions and delivery instructions stipulated on the purchase order.

17.2.5. The information on invoices and documents relating to delivery must comply with

the minimum data requirements as defined by the National Department of Health.

17.2.6. Invoices must reflect both the registered product name of the item and the item

description as it appears in the contract circular and Master Procurement

Catalogue (MPC).

17.2.7. Original invoices and proof of delivery must be authorised by a delegated official at

the designated delivery point. These documents must be delivered to the authority

responsible for payment. This may or may not be the same as the delivery address


Page | 18 of 24

stipulated on the purchase order. Suppliers are required to know where documents

must be delivered.

17.2.8. The supplier must ensure that products are delivered in accordance with the

appropriate conditions of storage, as per product's conditions of registration.

Delivery is deemed to terminate upon signature of receipt by the delegated official

as contemplated in paragraph 17.2.7

17.2.9. Discrepancies between invoice and physical stock, or damaged stock, will be

reported to the contracted supplier within a reasonable time or as arranged with

the supplier. This time period must make provision for the quantities received to be

checked upon receipt of delivery.

17.2.10. Contracted suppliers will be responsible for collection of goods delivered

erroneously, or in the incorrect condition as formally arranged in consultation with

the facility. The Participating Authorities may recoup any expenses associated with

failure to collect such goods in accordance with the agreement.

17.3. CONTINUITY OF SUPPLY

17.3.1. Contracted suppliers must:

have at least two months supply of the estimate at the start of the contract,

maintain sufficient stock to meet demand throughout the duration of the

contract;

inform the National Department of Health at first knowledge of any

circumstances that may result in interrupted supply, including but not limited to:

1. regulatory action which may impact on their GMP status or that of entities

on which they are reliant;

2. any anticipated problems associated with the availability of active

pharmaceutical ingredient (API);

3. industrial action;

4. challenges with manufacturing pipeline;

5. any other supply challenges.

direct official communication relating to continuity of supply to

[email protected], as well as Participating Authorities;

direct official communication relating to payment challenges to

[email protected], as well as Participating Authorities.

This official communication must include detail of corrective actions taken by the

contracted supplier to ensure continuity of supply.

17.3.2. It is the responsibility of the contracted supplier to ensure continuous availability

and supply of contracted items. In the event that the contracted supplier is unable


Page | 19 of 24

to supply in terms of 17.3.1 above, the contracted supplier will source alternative

product of acceptable quality and up to the same quantity as required in terms of

the contract. The substitute item will be supplied at the current price of the

contracted item.

17.3.3. Suppliers using the mechanism stipulated in 17.3.2 above may also be required to

pay penalties for supply exceeding the contractual lead time as stipulated in the

General Conditions of Contract Paragraph 22.

17.3.4. In terms of the General Conditions of Contract and Special Requirements and

Conditions of Contract, the Participating Authorities may purchase outside the

contract in order to meet its requirements if the item(s) are urgently required and

not immediately available.

18. PACKAGING AND LABELLING

18.1. PACKAGING

18.1.1. Suppliers must ensure that products delivered are received in good order at the

point of delivery. Packaging must be suitable for further dispatch, storage and

stacking according to Good Wholesaling Practice and Good Distribution Practice.

18.1.2. Packaging must be suitable for transportation and should prevent exposure to

conditions that could adversely affect the stability and integrity of the product.

18.1.3. The packing must be uniform for the duration of the contract period. All products

must be packed in acceptable containers, specifically developed for the product.

18.1.4. The number of units in the unit pack, shelf pack and shipper pack must be

completed in the Bid Response Document.

18.1.5. Where a particular stacking and storage configuration is recommended by the

supplier, this should be clearly illustrated on the outer packaging.

18.1.6. Where the contents of the shipper pack represents a standard supply quantity of

an item, the following must be adhered to:

Outer packaging flanges must be sealed with suitable tape that will clearly

display evidence of tampering.

The contents must be packed in neat, uniform rows and columns that will

facilitate easy counting when opened.

18.1.7. Where the contents of a shipper pack represents a non-standard supply quantity,

the following must be adhered to:

Outer packaging flanges must be sealed with suitable tape that will clearly

display evidence of tampering.

The shipper pack must contain only one product, mixing of multiple items in a

single shipper is not allowed.


Page | 20 of 24

The outer packaging must be clearly marked as a "Part Box".

18.2. LABELLING

18.2.1. All containers, packaging and cartons must be clearly labelled. Bulk packs must be

labelled in letters not less than font size 48.

The following information must be clearly and indelibly printed on all shelf and

shipper packs, including any part boxes:

Item name as contained in the contract circular and the Master Procurement

Catalogue (MPC);

Registered product name (if applicable);

Number of units in pack (e.g. for bulk packs 80 x 10 x 100s);

Batch number;

Expiry date;

Storage conditions;

Barcode.

18.2.2. Where the contents of the shipper requires special attention in terms of storage

and/or handling, e.g. thermolabile, high-scheduled or cytotoxic products, such

instructions must be clearly and visibly indicated on the outer packaging on a

brightly coloured background.

18.2.3. Unit packs must be labelled in accordance with Regulation 8 of the General

Regulations published in terms of the Medicines and Related Substances Act, Act

101 of 1965, as amended. The label must include a barcode.

18.3. BARCODES

18.3.1. It is mandatory that all products supplied must include a barcode (number plus

symbology). All shipper, shelf and unit packs must be marked with the appropriate

number and symbology. The European Article Numbering Code 13 (EAN 13) has

been accepted as standard.

18.3.2. Suppliers are encouraged to include a 2D barcode or similar on their packaging

that will include the following information:

Item name as contained in the contract circular and the Master Procurement

Catalogue (MPC);

Registered product name (if applicable);

Dosage form and strength;

Pack size;

Batch number;


Page | 21 of 24

Expiry date.

19. QUALITY

Products must conform with the conditions of registration of the product with Medicines

Control Council for the full duration of this contract.

20. SHELF-LIFE

20.1. Unless the stability of a product has required the MCC to approve a shorter shelf life,

products must have a shelf-life of at least 18 months upon delivery.

20.2. Contracted suppliers may apply in writing to Participating Authorities to supply a

product with a shorter shelf life provided that:

Applications are accompanied by an undertaking that such short-dated

products will be unconditionally replaced or credited before or after expiry; and

applications are approved before execution of orders; and

such products must be collected by the supplier at their own cost; and

failure to collect the products within 30 days after written notification to the

supplier will result in the disposal of the product by the Participating Authority

for the account of the supplier.

20.3. If short-dated products are delivered without the aforementioned undertaking the

following discount formula will be applied for invoicing of short-dated products:

A = (18 – months to date of expiry) x 2% x consignment value short dated product.

Therefore, amount to be invoiced is: Consignment value minus A, where A is the

value of the outcome of the discount formula.

20.4. Unless otherwise agreed to in terms of 20.2, any Participating Authority may, without

prejudice, decline to accept product with a shelf-life of less than 18 months.

21. POST AWARD

21.1. MONITORING

21.1.1. The management of the contract is the responsibility of the National Department of

Health. All correspondence in this regard must be directed to the Director: Affordable

Medicines.

21.1.2. Contracted suppliers must advise the Director: Affordable Medicines at first

knowledge of any unforeseeable circumstances that may adversely affect supply


Page | 22 of 24

against the contract. Full particulars of such circumstances must be provided by the

supplier as contemplated in paragraph 17.3.

21.1.3. The National Department of Health, in collaboration with the other Participating

Authorities, will monitor the performance of contracted suppliers and maintain a

scorecard for compliance to the terms of this contract as follows:

Compliance with delivery lead times;

Percentage of orders supplied in full first time;

Compliance with reporting requirements according to reporting schedule and

reporting mechanism. As a minimum suppliers will be required to submit the

following information in a specified format and via a mechanism defined by the

National Department of Health:

All transactional data relating to orders;

A monthly age analysis;

Pipeline data;

Status of outstanding orders.

Attendance of compulsory quarterly meetings: The National Department of

Health will hold quarterly meetings with suppliers to review the next quarter's

demand, as well as supplier performance.

21.1.4. The National Department of Health will request Participating Authorities to impose

penalties, where deemed necessary, as per Paragraph 21 and 22 of the General

Conditions of Contract.

21.1.5. Non-compliance of contracted suppliers in terms of this contract may influence

participation in future contracts .

21.2. REPORTING

21.2.1. National Department of Health will provide an indication of reporting requirements

at the compulsory briefing session and successful bidders will be assisted with

adopting these requirements.

21.2.2. The National Department of Health may, from time to time and within reason, add

to the reporting requirements. Any changes to reporting requirements or the

reporting mechanism will be communicated in writing by the Director: Affordable

Medicines.


Page | 23 of 24

21.3. CEDING, MERGERS, TAKE OVERS AND CHANGES IN SUPPLIER

DETAILS

21.3.1. Where a contracted supplier plans to merge with or is going to be acquired by

another entity, or plans to cede a contract the contracted supplier must inform the

National Department of Health in writing at first knowledge of such an event.

21.3.2. The National Department of Health reserves the right to agree to the transfer of

contractual obligations to the new supplier under the prevailing conditions of contract

or to cancel the contract.

21.3.3. A contracted supplier must inform the National Department of Health at first

knowledge of any changes to address, name, or contact details.

21.4. THIRD PARTIES

21.4.1. Participating Authorities will not make a payment to or consult with a third party.

21.4.2. No third party is entitled to put an account of a Participating Authority on hold.

21.5. CONTACT DETAILS

Postal address Director: Affordable Medicines, Private Bag X828, Pretoria, 0001

Physical address Director: Affordable Medicines, Civitas Building, 242 Struben Street, Cnr Thabo Sehume Street, Pretoria, 0001

Please use the following e-mail address and contact persons for any queries

relating to bidding process:

Ms B May Ms M Rasengane

Tel: (012) 395 8442 Tel: (012) 395 9452

Fax number: (012) 395 8823

Email: [email protected]


Page | 24 of 24

22. ABBREVIATIONS

The abbreviations used in this document signify the following:

API Active Pharmaceutical Ingredient

B-BBEE Broad-Based Black Economic Empowerment

BEC Bid Evaluation Committee

CD Compact Disc

CSD Central Supplier Database

EAN European Article Number

GMP Good Manufacturing Practice

MCC Medicines Control Council

MPC Master Procurement Catalogue

NDoH National Department of Health

PDF Portable Document Format

RoE Rate of Exchange

SARS South African Revenue Service

VAT Value Added Tax

hp09-2016sd: the supply and delivery of solid dosage … · [email protected] ranbaxy...

Documents